An Animal Model of Combined Pituitary Hormone Deficiency Disease by Colvin, Stephanie C.
Graduate School ETD Form 9 
(Revised 12/07)       
PURDUE UNIVERSITY 
GRADUATE SCHOOL 
Thesis/Dissertation Acceptance 
This is to certify that the thesis/dissertation prepared 
By  
Entitled
For the degree of   
Is approved by the final examining committee: 
       
                                              Chair 
       
       
       
To the best of my knowledge and as understood by the student in the Research Integrity and 
Copyright Disclaimer (Graduate School Form 20), this thesis/dissertation adheres to the provisions of 
Purdue University’s “Policy on Integrity in Research” and the use of copyrighted material.  
      
Approved by Major Professor(s): ____________________________________
                                                      ____________________________________ 
Approved by:   
     Head of the Graduate Program     Date 
Stephanie C. Colvin
An Animal Model of Pediatric Combined Pituitary Hormone Deficiency Disease
Doctor of Philosophy
Stephen F. Konieczny S.J. Rhodes
Emily Walvoord Teri Belecky-Adams
B.P. Herring Randall Roper
S.J. Rhodes
N. Lees 6/9/10
Graduate School Form 20 
(Revised 1/10)
PURDUE UNIVERSITY 
GRADUATE SCHOOL 
Research Integrity and Copyright Disclaimer 
Title of Thesis/Dissertation: 
For the degree of ________________________________________________________________ 
I certify that in the preparation of this thesis, I have observed the provisions of Purdue University 
Teaching, Research, and Outreach Policy on Research Misconduct (VIII.3.1), October 1, 2008.*
   
Further, I certify that this work is free of plagiarism and all materials appearing in this 
thesis/dissertation have been properly quoted and attributed. 
I certify that all copyrighted material incorporated into this thesis/dissertation is in compliance with 
the United States’ copyright law and that I have received written permission from the copyright 
owners for my use of their work, which is beyond the scope of the law.  I agree to indemnify and save 
harmless Purdue University from any and all claims that may be asserted or that may arise from any 
copyright violation. 
______________________________________ 
Printed Name and Signature of Candidate 
______________________________________ 
Date (month/day/year) 
*Located at http://www.purdue.edu/policies/pages/teach_res_outreach/viii_3_1.html
An Animal Model of Pediatric Combined Pituitary Hormone Deficiency Disease
Doctor of Philosophy
Stephanie C. Colvin
06/12/10
AN ANIMAL MODEL OF COMBINED PITUITARY HORMONE DEFICIENCY 
DISEASE 
 
 
A Dissertation 
Submitted to the Faculty 
of 
Purdue University 
by 
Stephanie C. Colvin 
 
 
In Partial Fulfillment of the 
Requirements for the Degree 
of 
Doctor of Philosophy 
 
 
August 2010 
Purdue University 
Indianapolis, Indiana 
ii
 
 
 
 
 
 
 
 
 
 
 
I dedicate this dissertation to my family, especially… 
To my Dad, for instilling his favorite motto “Endeavor to Persevere” 
To my Mom, without your love, wisdom, and encouragement, I would not be the person I 
am today 
To my brother, Dustin, who continues to teach me aspects about life in ways no one else 
can 
To my husband, Scott, for your love, encouragement, and understanding 
To my daughter, Cate, for being so wonderfully you 
iii
 
ACKNOWLEDGMENTS 
 
 
 
It is a privilege to acknowledge the members of my graduate committee: Dr. 
Stephen Konieczny, Dr. Simon Rhodes, Dr. Paul Herring, Dr. Teri Belecky-Adams, Dr. 
Randall Roper, and Dr. Emily Walvoord. Your insight and advice was extremely 
valuable to my success throughout my graduate education. I would also like to extend my 
gratitude to my friends and colleagues in the Rhodes lab, both past and present: Dr. Jesse 
Savage, Dr. Chad Hunter, Rachel Mullen, Tafadzwa Mwashita, Marin Garcia, Dr. 
Zachary Neeb, Christine Hammer, Aaron Showalter, Qi ‘Sophia’ Liu, Krystal Renner, 
Brooke West, Dr. Kyle Sloop, Soyoung Park, Raleigh Malik, and Dr. Kelly Prince. I 
want to thank members of the departments where the Rhodes lab has called home, Dr. N. 
Douglas Lees, Dr. Dring Crowell, Dr. Kathleen Marrs, Dr. Guoli Dai, Suzanne Merrel, 
and Erin McDaniel of the IUPUI Department of Biology, and Tracy McWilliams, 
Marlene Brown, Joyce Lawrence, Dr. David Basile, Dr. Glenn Bohlen, Dr. Richard Day, 
Dr. Patricia Gallagher, Dr. Steven Kempson, Dr. Frederick Pavalko, Dr. Michael Sturek, 
Dr. Patrick Fueger, Dr. Christine Quirk, Dr. Suzanne Young, Dr. Min Zhang, Emily Blue, 
Rebekah Jones, Ketrija Touw, Dr. Ryan Widau, and Dr. Jiliang ‘Leo’ Zhou of the IU 
Department of Cellular and Integrative Physiology. Finally, it is a pleasure to thank my 
friend and mentor, Dr. Simon Rhodes, without whose advice and encouragement the 
completion of this dissertation would have been impossible. Thank you, Simon, for your 
iv
 
sagacity, your guidance, allowing me the freedom to think independently, and for being 
such a strong advocate for me.  
 
 
v
 
TABLE OF CONTENTS 
 
 
 
Page 
LIST OF TABLES ............................................................................................................ vii 
LIST OF FIGURES ......................................................................................................... viii 
LIST OF ABBREVIATIONS ............................................................................................ ix 
ABSTRACT ..................................................................................................................... xiii 
CHAPTER ONE – INTRODUCTION 
     1.1  The Pituitary Gland and the Physiological Importance of Its Hormones ................1 
     1.2  Signaling Events and Transcription Factors That Regulate the 
Development of  the Pituitary ..................................................................................3 
1.3 The LIM-Homeodomain Transcription Factor LHX4 in Pituitary 
Development ..........................................................................................................15 
1.4 The LIM-Homeodomain Transcription Factor LHX3 in Pituitary and 
Nervous System Development ...............................................................................18 
1.5 Diseases Associated With Mutations Within the LHX3 Gene ...............................20  
CHAPTER TWO – MATERIALS AND METHODS 
2.1 DNA Cloning and Gene Targeting Vector Construction .......................................31 
2.2 Identification of Homologous Recombinants ........................................................34 
2.3 Genotyping and Breeding of Knock-In Mice ........................................................37 
     2.4  Histology and Immunohistochemistry ...................................................................39 
     2.5  RNA Analyses .......................................................................................................40 
     2.6  Microscopy ............................................................................................................42      
vi
Page 
     2.7  Hormone Analyses .................................................................................................42 
     2.8  General Molecular Techniques ..............................................................................44 
     2.9  Statistical Analyses ................................................................................................46 
CHAPTER THREE – A MOUSE MODEL OF HUMAN PEDIATRIC COMBINED 
PITUITARY HORMONE DEFICIENCY DISEASE 
     3.1  Introduction ............................................................................................................48 
     3.2  Results ....................................................................................................................49 
CHAPTER FOUR – DISCUSSION AND CONCLUSIONS ...........................................71 
BIBLIOGRAPHY ..............................................................................................................85 
VITA ................................................................................................................................101 
vii
 
 
LIST OF TABLES 
 
 
 
Table                Page 
 
1.1  Mutations within the LHX4 gene associated with combined pituitary hormone 
deficiency diseases .....................................................................................................28 
1.2  Mutations within the LHX3 gene associated with combined pituitary hormone 
deficiency diseases .....................................................................................................30 
3.1 Reproductive performance of Lhx3 W227ter mice ......................................................56 
 
  
        viii
LIST OF FIGURES 
 
 
 
Figure                Page 
 
1.1 Development of the anterior pituitary gland within mammals .................................25 
1.2 Transcriptional regulation of anterior pituitary development ...................................26 
2.1 Generating the construct ...........................................................................................47 
3.1 Lhx3W227ter/W227ter mice are viable ..............................................................................57 
3.2 Lhx3W227ter/W227ter mice are dwarfed ..........................................................................59 
3.3 Deficiencies in the growth hormone and thyroid hormone pituitary signaling 
axes underlie dwarfism in Lhx3W227ter/W227ter mice ....................................................61 
3.4 Altered expression of dimeric hormone transcripts ..................................................63 
3.5 Sexual maturation and fertility are impaired in Lhx3W227ter/W227ter mice ...................65 
3.6 PRL deficiency and infertility in Lhx3W227ter/W227ter female mice .............................67 
3.7 Decreased population of corticotrope cells in the pituitaries of 
Lhx3W227ter/W227ter mice ..............................................................................................69 
3.8 Altered gene expression of transcription factors involved in pituitary 
development ..............................................................................................................70 
ix
 
LIST OF ABBREVIATIONS 
 
 
 
Adrenocorticotropic hormone      ACTH 
Alpha glycoprotein subunit       GSU 
Alpha melanocyte-stimulating hormone     MSH 
Arginine vasopressin        AVP 
Base pair        bp 
Bone morphogenetic protein      BMP 
Calf intestinal alkaline phosphatase     CIAP 
Central nervous system      CNS 
Combined pituitary hormone deficiency    CPHD 
Complementary DNA       cDNA 
Corticotropin-releasing hormone     CRH 
Days post coitum       dpc 
Diaminobenzidine       DAB 
Diphtheria toxin-A       DTA 
Embryonic stem cells       ES cells 
Enzyme-linked immunosorbant assay    ELISA 
Fibroblast growth factor      FGF 
Follicle-stimulating hormone      FSH
x
 
Follicle-stimulating hormone beta     FSH 
Forkhead box        FOX 
Glyceraldehyde-3-phosphate dehydrogenase    GAPDH 
Gonadotropin-releasing hormone     GnRH 
Gonadotropin-releasing hormone receptor    GnRH-R 
Growth hormone        GH 
Growth hormone-releasing hormone     GHRH 
Growth hormone-releasing hormone receptor   GHRHR 
High mobility group       HMG 
Holoprosencephaly       HPE 
Homeodomain       HD 
Immunohistochemistry      IHC 
Insulin growth factor-1      IGF-1 
Kilobases        kb 
Kilodaltons        kDa 
Luria-Bertani broth       LB 
LIM homeobox 3       LHX3 
LIM homeobox 4       LHX4 
LIM homeodomain       LIM-HD 
Luteinizing hormone        LH 
Luteinizing hormone beta      LH 
Magnetic resonance imaging      MRI 
Nuclear factor-1       NF1 
xi
 
Open reading frame       ORF 
Oral ectoderm        OE 
Orthodenticle homeobox 2      OTX2 
Oxytocin        OT 
Paired homeobox       PAX 
Phosphate buffered saline      PBS 
Phosphoglycerate kinase      PGK 
Polymerase chain reaction       PCR 
Pro-opiomelanocortin       POMC 
Prolactin         PRL 
Prophet of Pit-1       PROP1 
Reverse transcriptase-PCR      RT-PCR 
Sex-determining region Y      SRY 
Sine oculis homeobox       SIX 
Sonic hedgehog        SHH 
SRY-box        SOX 
Specificity protein-1       SP-1 
Steroidogenic factor 1       SF1 
Thyroid-stimulating hormone      TSH 
Thyroid-stimulating hormone beta      TSH 
Thyrotropin-releasing hormone     TRH 
Triiodothyronine       T3 
xii
 
Thyroxine        T4 
Wingless/integrated protein      WNT 
xiii 
ABSTRACT 
 
 
 
Colvin, Stephanie C. Ph.D., Purdue University, August 2010. An Animal Model of 
Pediatric Combined Pituitary Hormone Deficiency Disease. Major Professor: Simon J. 
Rhodes. 
 
 
 
LHX3 is a LIM-homeodomain transcription factor that has essential roles in 
pituitary and nervous system development in mammals. Children who are homozygous 
for recessive mutations in the LHX3 gene present with combined pituitary hormone 
deficiency disease (CPHD) characterized by deficits of multiple anterior pituitary 
hormones. Most LHX3 patients also present with additional defects associated with the 
nervous system including a characteristic limited head rotation and sometimes deafness. 
However, of the 10 types of LHX3 mutation described to date, one mutation type 
(W224ter) does not result in the limited head rotation, defining a new form of the disease. 
W224ter patients have CPHD but do not have nervous system symptoms. Whereas other 
mutations in LHX3 cause loss of the entire protein or its activity, the W224ter mutation 
causes specific loss of the carboxyl terminal of the LHX3 protein—a region that we have 
shown to contain critical regulatory domains for pituitary gene activation. To better 
understand the molecular and cellular etiology of CPHD associated with LHX3 gene 
mutations, I have generated knock-in mice that model the human LHX3 W224ter disease. 
xiv 
The resulting mice display marked dwarfism, thyroid disease, female infertility, and 
reduced male fertility. Immunohistochemistry, real-time quantitative polymerase chain 
reaction (PCR), and enzyme-linked immunosorbant assays (ELISA) were used to 
measure hormones and regulatory factor protein and RNA levels, an approach which is 
not feasible with human patients. We have generated a novel mouse model of human 
pediatric CPHD. Our findings are consistent with the hypothesis that the actions of the 
LHX3 factor are molecularly separable in the nervous system and pituitary gland. 
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CHAPTER ONE 
 
INTRODUCTION 
 
 
 
1.1 The Pituitary Gland and the Physiological Importance of Its Hormones 
The pituitary gland, or hypophysis, is a composite organ located at the base of the 
brain within a bony pocket termed the sella turcica. This endocrine organ is derived from 
two different embryonic origins. The neurohypophysis is derived from the ventral 
diencephalon and is therefore neuroectodermal in origin. It includes the pars nervosa 
(posterior pituitary), the infundibular stalk, and the median eminence. At the same time 
during development, an invagination of the oral ectoderm into a rudimentary structure, 
termed Rathke’s pouch, gives rise to the development of the adenohypophysis. The 
adenohypophysis consists of the pars distalis (anterior pituitary), the pars intermedia 
(intermediate pituitary), and the pars tuberalis (Figure 1.1).  
These two different embryonic structures give rise to the three different lobes of 
the pituitary gland, and each lobe has its own physiological functions. The posterior lobe 
of the pituitary is composed of neuronal axons that descend from the hypothalamus. Two 
different peptide hormones, arginine vasopressin (AVP) and oxytocin (OT), are 
synthesized within the hypothalamus and exported to the posterior pituitary for secretion. 
Neural signals from the hypothalamus initiate the release of these hormones from the 
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posterior pituitary into the bloodstream. Arginine vasopressin, or anti-diuretic hormone, 
serves to control water retention within the body, while oxytocin has roles in lactation 
and uterine contraction during childbirth. The intermediate lobe of the pituitary is 
responsible for the production and secretion of -melanocyte-stimulating hormone 
(MSH), which has roles in skin pigmentation. While a more defined role for the 
intermediate lobe has been identified in amphibians, the human intermediate lobe appears 
to be less important as it is sometimes absent in adults, and when present, consists only of 
a thin layer of cells between the posterior and anterior lobes. The anterior lobe of the 
pituitary contains five hormone-secreting cell types that are responsible for the secretion 
of six different hormones. The corticotropes secrete adrenocorticotropin (ACTH), which 
is a product of the pro-opiomelanocortin (POMC) gene and acts on the adrenal glands to 
assist the body in its response to stress. The gonadotropes discharge both luteinizing 
hormone (LH) and follicle-stimulating hormone (FSH), both of which function to 
regulate the development, growth, and maturation of the reproductive system. The 
somatotropes release growth hormone (GH), which has a role in metabolism in addition 
to the regulation of the growth of muscle, bone, and other organs. The thyrotropes 
produce thyroid-stimulating hormone (TSH), which acts on the thyroid to promote the 
production and secretion of thyroxine (T4) and triiodothyronine (T3). The lactotropes 
secrete prolactin (PRL), which plays a major role in lactation (Figure 1.1). Three of these 
hormones, TSH, LH, and FSH, are heterodimeric in nature and consist of a common -
glycoprotein subunit (GSU) and a unique -subunit (TSH, LH, and FSH). The 
release of these hormones from the anterior pituitary is tightly regulated through the 
secretion of both inhibiting and releasing hormones from the hypothalamus. These 
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inhibiting and releasing hormones are released into the blood stream from the 
hypothalamus and travel to the anterior pituitary where they bind to the surface 
membrane receptors of the hormone-secreting cells to promote or inhibit the secretion of 
those hormones (Figure 1.1). For example, once corticotropin-releasing factor is secreted 
from the hypothalamus, it travels to the anterior pituitary where it binds to the 
corticotropin-releasing factor receptor on the corticotrope cells to promote the release of 
ACTH.  
 
1.2 Signaling Events and Transcription Factors That Regulate the Development of the 
Pituitary 
Numerous studies across several different species have shown that inductive 
signaling events between the ventral diencephalon and Rathke’s pouch must occur for 
proper pituitary development (Figure 1.2) (Daikoku, Chikamori et al. 1982; Watanabe 
1982; Watanabe 1982; Kawamura and Kikuyama 1995; Gleiberman, Fedtsova et al. 
1999). Diffusible signaling molecules produced by the ventral diencephalon and the oral 
ectoderm that have been found to have significant effects on the induction and growth of 
Rathke’s pouch include members of the bone morphogenetic protein (BMP), fibroblast 
growth factor (FGF), wingless/integrated (WNT), and hedgehog families. Extrinsic 
signals and transcription factors expressed from the ventral diencephalon and developing 
infundibulum important for pouch development include BMP4, FGF8, FGF10, FGF18, 
WNT5a, SOX3 and NKX2.1 (Kimura, Hara et al. 1996; Ericson, Norlin et al. 1998; 
Takuma, Sheng et al. 1998; Norlin, Nordstrom et al. 2000; Ohuchi, Hori et al. 2000; 
Alatzoglou, Kelberman et al. 2009). Sonic hedgehog (SHH) is another extrinsic signal 
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necessary for early pituitary development. SHH expression is absent in the cells of oral 
ectoderm that invaginate to form Rathke’s pouch; however, its expression is maintained 
in the ventral diencephalon and the oral ectoderm surrounding Rathke’s pouch during 
early pituitary development (Treier, Gleiberman et al. 1998; Treier, O'Connell et al. 
2001). Intrinsic signals within the pouch itself are also important for the proper 
development of the pituitary. WNT4 is expressed in the oral ectoderm and developing 
Rathke’s pouch in addition to BMP2 and BMP7 also being expressed in the pouch during 
early pituitary development (Ericson, Norlin et al. 1998; Treier, Gleiberman et al. 1998). 
Rathke’s pouch eventually separates from the oral ectoderm with the dorsal cells of the 
pouch destined to populate the intermediate lobe of the pituitary and the ventral cells of 
the pouch acquiring an anterior pituitary cell fate. The combination of these extrinsic and 
intrinsic signaling molecules establishes opposing dorsal-to-ventral and ventral-to-dorsal 
signaling gradients. These opposing signaling gradients prime transcription factors to be 
expressed in a spatial manner within the developing pouch and set up the stratification of 
the developing hormone-secreting cell types with the corticotropes, somatotropes, and 
lactotropes appearing in the dorsal side of the anterior lobe, the thyrotropes located in the 
central part of the lobe, and the gonadotropes occupying the ventral part of the anterior 
lobe (Dasen, O'Connell et al. 1999; Kioussi, O'Connell et al. 1999; Scully and Rosenfeld 
2002). While this regionalization of the hormone-secreting cell types of the anterior 
pituitary persists in birds, teleost fish, amphibians, and reptiles, it is not retained in adult 
mammalian pituitaries.  
The specification of the unique identities of the hormone-secreting cell types 
within the anterior pituitary is dependent on a transcription factor cascade that is 
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facilitated by the signaling gradients established between the ventral diencephalon and 
Rathke’s pouch (Figure 1.2). Several transcription factors have been found to be requisite 
for the appropriate development and maintenance of the mature anterior pituitary gland 
including GLI2, OTX2, SOX2, PAX6, SIX3, SIX6, PITX1, PITX2, HESX1, LHX3, 
LHX4, PROP1, PIT-1, and SF1. 
GLI2 is a member of the GLI family of transcription factors which are known as 
mediators of SHH signaling in vertebrates (Ruiz i Altaba, Palma et al. 2002). The GLI 
transcription factors are composed of a centrally located DNA-binding domain, a 
transcription activation domain located within the carboxyl terminus of the protein, and 5 
C2-H2 zinc fingers. GLI2 has a broad expression pattern throughout most of the 
mesoderm and ectoderm early in development and is later expressed in the developing 
somites and limbs (Mo, Freer et al. 1997). It has important roles in the appropriate 
development of a variety of systems including the developing nervous system, the 
developing skeletal system, and limb buds and can act as both a transcriptional activator 
and repressor (Mo, Freer et al. 1997; Aza-Blanc, Lin et al. 2000; Roessler, Du et al. 
2003). Mice homozygous for a null allele of the Gli2 gene die embryonically with defects 
in the development of the brain and spinal cord, no floor plate, and some mild 
craniofacial defects (Mo, Freer et al. 1997; Ding, Motoyama et al. 1998; Matise, Epstein 
et al. 1998; Park, Bai et al. 2000). Mutations within the human GLI2 gene have been 
found in a heterozygous state and are inherited in an autosomal dominant manner. The 
mutations appear to ablate the function of the GLI2 allele in which they are found. These 
patients present with varying forms of holoprosencephaly (HPE) with the pituitary and 
facial structures the most sensitive to the reduction in GLI2 activity as the common 
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features between these patients were hypoplastic/aplastic anterior pituitaries and variable 
craniofacial abnormalities (Roessler, Du et al. 2003).  
The Orthodenticle homeobox 2 (OTX2) gene encodes a paired-class 
homeodomain transcription factor and is expressed in the neuroepithelium of most of the 
forebrain and midbrain during development (Simeone, Acampora et al. 1993). Targeted 
disruptions within the murine Otx2 gene result in defects in gastrulation and no anterior 
head or brain structures leading to embryonic lethality (Acampora, Mazan et al. 1995; 
Ang, Jin et al. 1996). Otx2 expression has also been found in the developing eye, 
pituitary, hypothalamus, brain, and thalamus, and human patients with mutations within 
the OTX2 gene display variable phenotypes representing abnormalities within these 
regions (Ragge, Brown et al. 2005; Hever, Williamson et al. 2006; Dateki, Fukami et al. 
2008; Diaczok, Romero et al. 2008; Wyatt, Bakrania et al. 2008; Henderson, Williamson 
et al. 2009; Tajima, Ohtake et al. 2009; Dateki, Kosaka et al. 2010). OTX2 appears to 
have a role in pituitary development as it is expressed in the developing pituitary, some 
human patients with mutations within the OTX2 gene display pituitary insufficiency, and 
in vitro studies have shown that OTX2 is capable of binding and activating transcription 
from the HESX1, PIT1, and GNRH1 promoters (Diaczok, Romero et al. 2008; 
Henderson, Williamson et al. 2009; Tajima, Ohtake et al. 2009; Dateki, Kosaka et al. 
2010).  
A member of the SRY-related high mobility group (HMG) box family of 
transcription factors, SOX2, has been shown to have important roles early in pituitary 
development. Sox2 is expressed early in mouse development with roles in the developing 
CNS, sensory placodes, branchial arches, and gut endoderm including the esophagus, the 
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trachea, and the inner ear (Collignon, Sockanathan et al. 1996; Wood and Episkopou 
1999; Williamson, Hever et al. 2006; Hume, Bratt et al. 2007). Sox2 expression is found 
throughout Rathke’s pouch as early as e11.5 in the developing mouse embryo; however, 
by e18.5, its expression is found scattered throughout the pouch and within the 
proliferating cells of the dorsal zone (Kelberman and Dattani 2006). In the adult anterior 
pituitary, Sox2 expression is maintained in a small population of cells lining the pituitary 
cleft and scattered throughout the parenchyma and represent progenitor cells within the 
pituitary as they are able to differentiate into all pituitary cell types. Cells that continue to 
express Sox2 in the adult pituitary gland are proposed to have a role in the plasticity of 
the gland in its response to changing physiological demands (Fauquier, Rizzoti et al. 
2008). Disruptions within the murine Sox2 gene result in some embryonic and perinatal 
lethality (Avilion, Nicolis et al. 2003; Ferri, Cavallaro et al. 2004). The surviving mice 
demonstrate the importance of Sox2 in the developing nervous system and pituitary with 
defects in behavior, various brain structures, and bifurcated Rathke’s pouch with 
decreases in somatotropes and gonadotropes (Kelberman and Dattani 2006; Alatzoglou, 
Kelberman et al. 2009). Mutations within the human SOX2 gene are associated with 
bilateral anophthalmia, or severe microphthalmia, developmental delay, esophageal 
atresia, sensorineural hearing loss, and genital abnormalities in male patients in addition 
to hypoplastic anterior pituitaries. Although the patients present with hypoplastic 
pituitaries, they all have a normal GH response and are diagnosed with isolated 
gonadotropin deficiency (Alatzoglou, Kelberman et al. 2009).  
PAX6 is a member of the conserved paired homeodomain PAX transcription 
factor family. Transcription of the Pax6 gene leads to the production of a transcription 
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factor containing both a paired DNA-binding domain and a homeodomain. PAX6 
expression is found in the developing eye, nervous system, pancreas, and pituitary, and 
studies in both human patients and mouse models with mutations in PAX6 show that it 
appears to be necessary for the proper development of those structures (Bentley, 
Zidehsarai et al. 1999; Terzic and Saraga-Babic 1999; Dohrmann, Gruss et al. 2000). In 
the developing pituitary, PAX6 plays a role in the dorsal-to-ventral signaling gradient 
that establishes the proper cell-type development within the anterior pituitary. In mice 
lacking any functional Pax6 alleles, this dorsal-to-ventral gradient is disrupted and these 
mice exhibit significantly reduced numbers of the dorsal somatotropes and lactotropes 
while there is an increase in ventral thyrotropes and gonadotropes (Kioussi, O'Connell et 
al. 1999).  
Members of the SIX family of transcription factors were identified through their 
homology to the Drosophila sine oculis homeobox gene. Two members of this family, 
Six3 and Six6, appear to have roles in pituitary development (Cheyette, Green et al. 
1994). Six3 expression is found within the anterior neural plate early in development, and 
later in derivatives of the anterior neural plate, including the ectoderm of the nasal cavity, 
the olfactory placode, Rathke’s pouch, and regions of the optic recess, hypothalamus, 
optic vesicles, retina, and lens placode (Oliver, Mailhos et al. 1995; Bovolenta, 
Mallamaci et al. 1998). The exact role of Six3 in pituitary development has been difficult 
to elucidate as Rathke’s pouch is never induced in Six3-/- mice (Lagutin, Zhu et al. 2003). 
Recently, however, severe pituitary dysmorphogenesis resulting in hypopituitarism has 
been observed in Six3+/-; Hesx1Cre/- doubly heterozygous mice demonstrating that Six3 
plays an essential role in normal pituitary development (Gaston-Massuet, Andoniadou et 
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al. 2008). Human patients with mutations within the homeodomain-encoding region of 
the SIX3 gene present with varying forms of holoprosencephaly (HPE), which is a severe 
malformation involving failure of the brain to separate into left and right halves (Wallis, 
Roessler et al. 1999). Six6 expression is more restricted than the expression of Six3, and 
is found in the developing hypothalamus, pituitary, neural retina, optic chiasm, and optic 
stalk (Jean, Bernier et al. 1999). Retinal hypoplasia, optic nerve defects, and pituitary 
hypoplasia are observed in animals lacking SIX6. A role for SIX6 has also been found 
during development in the repression of genes that encode cell cycle inhibitors suggesting 
that SIX6 promotes the proliferation of precursor cells within the developing retina and 
pituitary (Li, Perissi et al. 2002).  
Two bicoid-related homeodomain transcription factors, PITX1 and PITX2, play 
important roles in several developmental pathways including limb, heart, and pituitary 
organogenesis (Drouin, Lamolet et al. 1998; Gage, Suh et al. 1999). In pituitary 
development, PITX1 was first identified as a protein partner capable of synergistically 
activating pituitary target genes with another homeodomain transcription factor, PIT-1. It 
was also determined that PITX1 has a role in the activation of the POMC gene in 
corticotrope cells (Szeto, Ryan et al. 1996; Tremblay, Lanctot et al. 1998). Expression of 
PITX1 occurs early in pituitary development, and studies have shown that it is able to 
activate transcription from several pituitary hormone promoters including PRL, LH, 
FSH, TSH, GnRHR, and GH (Lamonerie, Tremblay et al. 1996; Szeto, Ryan et al. 
1996; Lanctot, Lamolet et al. 1997; Tremblay, Lanctot et al. 1998; Lanctot, Gauthier et 
al. 1999; Jeong, Chin et al. 2004). Synergy between PITX1 and other pituitary 
transcription factors, including SF1 and PIT-1, has to occur for the proper activation of its 
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target genes (Tremblay, Lanctot et al. 1998). In vitro and in vivo experiments have shown 
PITX1 to have a role in the proper expression of LHX3 and GSU (Tremblay, Lanctot et 
al. 1998; Charles, Suh et al. 2005). Mice lacking any functional PITX1 protein support 
these data with defects in gonadotrope, thyrotrope, and corticotrope development as well 
as defects in hindlimb and craniofacial development (Lanctot, Moreau et al. 1999; Szeto, 
Rodriguez-Esteban et al. 1999; Charles, Suh et al. 2005).  
PITX2 is also important in pituitary development as evidenced by Pitx2-/- 
knockout mice. Pitx2 null mice display abnormalities in pituitary development in addition 
to abnormalities in left-right asymmetry, heart, tooth, eye, and craniofacial development 
(Semina, Reiter et al. 1996; Gage and Camper 1997; Logan, Pagan-Westphal et al. 1998; 
Ryan, Blumberg et al. 1998; Yoshioka, Meno et al. 1998; Gage, Suh et al. 1999; Lin, 
Kioussi et al. 1999). A gene-dosage requirement for Pitx2 has been determined through 
studies done on mice bearing hypomorphic Pitx2 alleles. Pitx2 hypomorphs reveal that 
PITX2 is necessary for proper development and expansion of Rathke’s pouch and the 
proper expression of HESX1 and PROP1 during pouch development. These mice also 
reveal the importance of PITX2 for the appropriate differentiation of gonadotropes, 
thyrotropes, somatotropes, and lactotropes (Gage, Suh et al. 1999; Suh, Gage et al. 2002). 
The mechanism through which pituitary cell proliferation is regulated by PITX2 is 
mediated by the WNT/beta-catenin pathway. Signaling from the WNT/-catenin pathway 
converts PITX2 from repressor to activator allowing it to activate transcription from the 
target genes cyclin D2, cyclin D1, and c-Myc which promote pituitary cell proliferation 
(Kioussi, Briata et al. 2002; Baek, Kioussi et al. 2003). Mutations within the human 
PITX2 gene cause phenotypes similar to that seen in the Pitx2-/- mice with eye defects, 
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pituitary abnormalities, dental hypoplasia, and craniofacial defects which are associated 
with Reiger syndrome seen in human patients (Semina, Reiter et al. 1996).  
HESX1, or RPX, is a paired homeodomain transcription factor necessary for 
proper pituitary development. It is expressed early in the developing neural plate before 
being restricted to Rathke’s pouch (Thomas, Johnson et al. 1995; Hermesz, Mackem et 
al. 1996). HESX1 is the earliest pituitary marker within the invaginating oral ectoderm 
with expression noted around e9.0 in the developing mouse pituitary. However, its 
expression is downregulated as differentiation of the hormone-secreting cell types within 
the anterior pituitary occurs, so that by e15.5, HESX1 is no longer detectable (Gage, 
Brinkmeier et al. 1996; Hermesz, Mackem et al. 1996). Two other transcription factors in 
pituitary development have been linked to the strong expression of HESX1, initially 
followed by its expression being extinguished as the cell types differentiate. LHX3 has 
been shown to be requisite for initial HESX1 expression during early pituitary 
development, and PROP1 has been shown to repress HESX1 expression in time for the 
differentiation of the specific pituitary cell types (Gage, Brinkmeier et al. 1996; Hermesz, 
Mackem et al. 1996; Sheng, Zhadanov et al. 1996). Homozygous Hesx1-/- knockout mice 
have forebrain defects, defects in olfactory development, bifurcations in Rathke’s pouch, 
and defects in eye development in addition to other various brain abnormalities (Dattani, 
Martinez-Barbera et al. 1998). A human condition similar to this mouse model is septo-
optic dysplasia, which can present itself as any combination of optic nerve hypoplasia, 
pituitary hypoplasia, and midline abnormalities of the brain, such as the corpus callosum 
and septum pellucidum. Mutations within the human HESX1 gene have been associated 
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with this disorder in several patients (Dattani, Martinez-Barbera et al. 1998; Thomas, 
Dattani et al. 2001; Sobrier, Maghnie et al. 2006). 
The paired-class homeodomain transcription factor, Prophet of Pit-1 (PROP1), is 
specifically expressed in the developing anterior pituitary (Sornson, Wu et al. 1996; 
Sloop, McCutchan Schiller et al. 2000). Molecular studies analyzing the PROP1 protein 
show that it is capable of acting as both transcriptional activator and repressor with a 
conserved carboxyl-terminus containing the trans-activation domain and the 
homeodomain demonstrating repressive properties (Showalter, Smith et al. 2002; Guy, 
Hunter et al. 2004). The importance of proper Prop1 gene expression can be seen in both 
naturally occurring and genetically engineered mouse models. The Ames dwarf mouse is 
the result of a spontaneous mutation within the homeodomain of the Prop1 gene. These 
mice display deficits in somatotrope, lactotrope, and thyrotrope cells in addition to 
reduced gonadotropin hormone levels (Tang, Bartke et al. 1993; Andersen, Pearse et al. 
1995; Gage, Lossie et al. 1995; Gage, Brinkmeier et al. 1996; Sornson, Wu et al. 1996). 
The transcription factor PIT-1 is also absent in these mice suggesting that PROP1 is 
epistatic to PIT-1 in the transcriptional cascade involved in anterior pituitary 
development (Tang, Bartke et al. 1993; Andersen, Pearse et al. 1995; Gage, Lossie et al. 
1995; Gage, Brinkmeier et al. 1996; Sornson, Wu et al. 1996). The engineered Prop1-/- 
knockout mice have a similar phenotype to the Ames dwarf mice. However, in addition 
to the hormone deficiencies, deletion of Prop1 can be lethal as approximately 50% of 
Prop1 null mice die from respiratory distress syndrome (RDS) at birth (Nasonkin, Ward 
et al. 2004). More roles for PROP1 throughout pituitary development have been 
elucidated through further evaluation of Prop1-deficient mice and gain of function 
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experiments. These studies have shown that PROP1 plays a part in pituitary 
vascularization, the onset of puberty, and tumorigenesis within the pituitary (Cushman, 
Watkins-Chow et al. 2001; Vesper, Raetzman et al. 2006; Ward, Stone et al. 2006). 
Analyses of mice homozygous for mutations in both Prop1 and Lhx4, two transcription 
factors important in pituitary development, demonstrate an overlapping role early in 
pituitary development to promote the expansion of Rathke’s pouch and later for the 
appropriate differentiation of both corticotrope and gonadotrope cell types (Raetzman, 
Ward et al. 2002). Mutations within the human PROP1 gene are the most common 
known cause of combined pituitary hormone deficiency (CPHD), which is diagnosed 
when the production of growth hormone and at least one other hormone produced from 
the anterior pituitary is defective (Wu, Cogan et al. 1998). 
The first pituitary transcription factor to be identified was PIT-1 (POU1F1), 
which is a homeodomain transcription factor (Bodner, Castrillo et al. 1988; Ingraham, 
Chen et al. 1988). The proper development of the somatotrope, lactotrope, and thyrotrope 
cell lineages rely on PIT-1 expression within the anterior pituitary. PIT-1 acts within 
these cells to turn on the appropriate genes while repressing expression of inappropriate 
hormone genes (Dasen, O'Connell et al. 1999; Scully, Jacobson et al. 2000). Within the 
somatotrope, lactotrope, and thyrotrope cells, target genes of PIT-1 include GH, GHRHR, 
PRL, TSH, and thyroid hormone receptor beta type 2 (Steinfelder, Hauser et al. 1991; 
Rhodes, Krones et al. 1996; Iguchi, Okimura et al. 1999; Miller, Godfrey et al. 1999). 
PIT-1 is also able to bind to and activate transcription from its own promoter and a distal 
enhancer, which reinforces the commitment of the pituitary cell lineages dependent on 
PIT-1 expression (Rhodes, Chen et al. 1993; Rhodes, Krones et al. 1996). Two naturally 
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occurring mouse models exist that demonstrate the importance of PIT-1 in the 
development and specification of the somatotrope, lactotrope, and thyrotrope cell types. 
The Snell (dw) and Jackson (dwJ) dwarf mice carry recessive point or null mutations in 
Pit-1, respectively. These mice exhibit hypoplastic pituitaries with a dearth of 
somatotropes, lactotropes, and thyrotropes (Li, Crenshaw et al. 1990). Human patients 
with mutations within their PIT-1 gene are diagnosed with CPHD and exhibit a 
phenotype similar to the dwarf mice lacking GH, TSH, and PRL (Tatsumi, Miyai et al. 
1992).  
Steroidogenic factor 1 (SF1) is an orphan nuclear receptor transcription factor 
involved in the development of several endocrine tissues. SF1 has been shown to be an 
important regulator involved in both the hypothalamus-pituitary-adrenal axis and the 
hypothalamus-pituitary-gonad axis, with a role in the gene regulation of the enzymes that 
produce the sex steroids (Morohashi and Omura 1996). Mice lacking any functional SF1 
protein die postnatally with defects in ventromedial hypothalamic nuclei, absent gonadal 
and adrenal tissues, a lack of pituitary gonadotrope cells, and therefore undetectable 
levels of LH, FSH, and GnRHR (Ingraham, Lala et al. 1994; Luo, Ikeda et al. 1994; 
Sadovsky, Crawford et al. 1995; Shinoda, Lei et al. 1995). Mice with targeted disruption 
of SF1 just within the pituitary gondadotropes display hypogonadotropic hypogonadism, 
which suggests that proper expression of SF1 within the pituitary is necessary for normal 
development of reproductive organs (Zhao, Bakke et al. 2001).  
  
15 
 
1.3 The LIM-Homeodomain Transcription Factor LHX4 in Pituitary Development 
 LHX4 is a member of the LIM-homeodomain transcription factor family that 
contains two LIM domains that permit protein-protein interactions, and a centrally 
located homeodomain that serves as the DNA-binding motif of the protein (Hunter and 
Rhodes 2005). The human LHX4 gene spans over 45 kilobases on chromosome 1 and its 
transcription is controlled by a TATA-less promoter(s), which contains recognition 
elements for specificity protein 1 (Sp1) (Machinis, Pantel et al. 2001; Liu, Fan et al. 
2002; Yaden, Garcia et al. 2006; Liu, Luo et al. 2008). In vitro experiments have 
determined that LHX4 is capable of binding to promoters and activating transcription of 
several genes involved in pituitary development including GSU, GH, PRL, PIT-1, and 
FSH (Sloop, Dwyer et al. 2001; Kawamata, Sakajiri et al. 2002; West, Parker et al. 
2004; Machinis and Amselem 2005; Castinetti, Saveanu et al. 2008).  
While LHX3 and LHX4 share several similarities in protein structure, their 
expression patterns are different during development, and double- and single-gene 
targeting in mice reveals the individual importance of each protein during development. 
Expression of Lhx4 (or Gsh4) during mouse development is found in the hindbrain, the 
cerebral cortex, the pituitary gland, and the spinal cord (Li, Witte et al. 1994; Liu, Fan et 
al. 2002). It is detected early in the development of Rathke’s pouch at e9.5, and becomes 
more concentrated in the area of the pouch that will become the anterior pituitary by 
e12.5 while Lhx3 expression continues throughout the entire pouch. Lhx4 gene 
expression is considerably reduced throughout development with little detected in adult 
pituitaries whereas Lhx3 expression continues throughout development into adulthood 
(Sheng, Moriyama et al. 1997). Mice homozygous for a targeted gene disruption of Lhx4 
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die shortly after birth with lungs that do not inflate (Li, Witte et al. 1994). Lhx4+/- 
(heterozygous) mice appear to be unaffected. Similar to the Lhx3-/- mice, a definitive 
Rathke’s pouch forms in the Lhx4-/- mice, and growth of the pouch is arrested at this 
stage. While proliferation of the pouch is impaired and the anterior pituitary is severely 
hypoplastic, the pouch of Lhx4-/- mice contains cells of all the differentiated cell types, 
which is not the case with the Lhx3-/- mice where only a few corticotropes remain within 
the anterior pituitary (Li, Witte et al. 1994; Sheng, Moriyama et al. 1997). Apoptosis of 
pituitary precursor cells appears to be responsible for the hypoplastic anterior pituitary in 
the Lhx4 null mice (Raetzman, Ward et al. 2002). Expression of Lhx3 is impaired in 
Lhx4-/- and Lhx4/Prop1 double knockout mice, which indicates a role for Lhx4 in the 
proper expression of Lhx3, which is aided by Prop1 (Raetzman, Ward et al. 2002). The 
combination of the importance of LHX4 for cell survival and proper expression of LHX3 
indicates that LHX4 is necessary for appropriate expansion of the pouch during 
development. Lhx3 and Lhx4 appear to have more overlapping roles earlier in pouch 
development as Rathke’s pouch in double knockouts does not progress beyond an early 
rudimentary stage, whereas it develops into a more definitive pouch structure in the 
single knockouts (Sheng, Moriyama et al. 1997). Lhx4 also has an important role in the 
development of ventral motor neurons, as does Lhx3 (Sharma, Sheng et al. 1998).  
Lhx3 and Lhx4 appear to play separate roles in the function of pituitary 
stem/progenitor cells and gland maintenance. Although LHX4 expression is 
downregulated after anterior pituitary development, anterior pituitary stem/progenitor 
cells contained within a side population of the adult gland have been shown to express 
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LHX4. However, LHX3 expression was restricted to the main population of pituitary 
cells (Chen, Hersmus et al. 2005).  
Human mutations within the LHX4 gene have been found to exist in a 
heterozygous state (Table 1). Patients with mutations within LHX4 are diagnosed with 
CPHD with variable hormone deficiencies. All patients heterozygous for a LHX4 
mutation present with some degree of GH and TSH deficiency, but deficiency in the 
other anterior pituitary hormones (LH, FSH, ACTH, and PRL) is more variable. 
Hypoplasia of the anterior lobe, ectopic posterior pituitary, structural abnormalities of the 
sella turcica, chiari malformations in the brain, and respiratory distress syndrome are 
other variable features associated with LHX4 mutations (Machinis, Pantel et al. 2001; 
Tajima, Hattori et al. 2007; Castinetti, Saveanu et al. 2008; Pfaeffle, Hunter et al. 2008; 
Tajima, Yorifuji et al. 2009).  
The fact that LHX4 mutations exist in human patients in a heterozygous state 
suggests that the aberrant proteins being produced are acting in a dominant negative 
fashion, or haploinsufficiency is taking place, meaning the mutations within the LHX4 
gene result in reduced gene function and the effectiveness of the LHX4 protein produced 
from the functional allele is below the threshold necessary for developmental steps 
requiring LHX4. To date, studies suggest the latter is taking place with some evidence 
pointing to the instability of aberrant LHX4 proteins produced due to the mutation 
present in the gene (Machinis and Amselem 2005; Castinetti, Saveanu et al. 2008; 
Pfaeffle, Hunter et al. 2008; Tajima, Yorifuji et al. 2009). The phenotype of human 
patients with LHX4 mutations does not correspond to the observation of apparently 
normal pituitary physiology of Lhx4+/- mice (Li, Witte et al. 1994; Sheng, Moriyama et al. 
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1997; Raetzman, Ward et al. 2002). However, factors that could be contributing to this 
difference include the difference in biology between humans and rodents, genetic 
background effects, gene inactivation, and epigenetic effects. Compound heterozygosity 
within human patients is something else to consider; meaning, human patients could have 
another mutation within another gene important for LHX4 gene function throughout 
development, although none have been described to date.  
 
1.4 The LIM-Homeodomain Transcription Factor LHX3 in Pituitary and Nervous System 
Development 
LHX3 is another member of the LIM-homeodomain transcription factor family. 
The human LHX4 and LHX3 proteins are very similar, sharing 63% amino acid identity 
with 75%-95% homology observed in the LIM domains and the HD (Hunter and Rhodes 
2005; Mullen, Colvin et al. 2007). In addition to the LIM domains and the homeodomain, 
LHX3 also contains a major trans-activation domain for pituitary gene activation in its 
carboxyl terminus (Sloop, Dwyer et al. 2001). In both rodents and humans, transcription 
of the gene encoding LHX3 is regulated by two TATA-less GC-rich promoters that lie 
upstream of exons Ia and Ib, and involves the actions of specificity protein-1 (Sp1) and 
nuclear factor I (NFI) (Yaden, Garcia et al. 2006). Studies involving in vitro and in vivo 
methods have determined that Lhx4, Pitx1, Pitx2, Sox2, and FGFs, such as FGF8, are 
involved in the direct and indirect activation of Lhx3 (Takuma, Sheng et al. 1998; 
Tremblay, Lanctot et al. 1998; Raetzman, Ward et al. 2002; Charles, Suh et al. 2005; 
Rajab, Kelberman et al. 2008) (Figure 1.2). Transcription of the LHX3 gene produces two 
mRNA transcripts from which three protein isoforms are translated. The LHX3a and 
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LHX3b isoforms result from alternate use of exons Ia and Ib and therefore differ in their 
amino termini (Zhadanov, Bertuzzi et al. 1995; Sloop, Meier et al. 1999). The M2-LHX3 
isoform is a truncated isoform resulting from an internal methionine codon within the 
LHX3a transcript (Zhadanov, Copeland et al. 1995; Sloop, Meier et al. 1999; Sloop, 
Dwyer et al. 2001). These protein isoforms have different DNA binding and gene 
activation abilities and are therefore proposed to have individual roles during 
development (Sloop, Meier et al. 1999; Bridwell, Price et al. 2001; Sloop, Dwyer et al. 
2001; Savage, Yaden et al. 2003).  
In mice, Lhx3 maps to the proximal region of chromosome 2 and is an early 
marker for pituitary development. It is expressed as early as e8.5, and found in Rathke’s 
pouch and the closing neural tube around e9.5. Expression of Lhx3 is also found in the 
developing hindbrain, spinal cord, pineal gland, and the vestibular epithelium of the inner 
ear (Seidah, Barale et al. 1994; Bach, Rhodes et al. 1995; Zhadanov, Bertuzzi et al. 1995; 
Sheng, Zhadanov et al. 1996; Sharma, Sheng et al. 1998; Hume, Bratt et al. 2007). Lhx3 
is required for proper pituitary development and motor neuron specification as evidenced 
by the phenotype of the Lhx3-/- knockout mice (Sheng, Zhadanov et al. 1996; Sheng, 
Moriyama et al. 1997; Sharma, Sheng et al. 1998). These mice are stillborn, or die within 
24 hours of birth, and lack anterior and intermediate pituitary structures with four of the 
five hormone-secreting cell types absent—only a small population of corticotropes 
remain (Sheng, Zhadanov et al. 1996; Sheng, Moriyama et al. 1997). Consistent with this 
phenotype, molecular studies have shown that LHX3a is able to bind directly to 
promoter/enhancer regions of several genes involved in pituitary development and 
function including GSU, TSH, FSH, PRL, gonadotropin releasing hormone receptor, 
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and PIT-1 (Bach, Rhodes et al. 1995; Sloop, Meier et al. 1999; West, Parker et al. 2004; 
McGillivray, Bailey et al. 2005; Granger, Bleux et al. 2006). It is also required for proper 
expression of FOXL2, which is a transcription factor with implicated roles in the 
differentiation of pituitary cells that express GSU (Ellsworth, Egashira et al. 2006) 
(Figure 1.2). Spinal cord motor neuron development is also impaired in Lhx3-/-/Lhx4-/- 
mice, and further evidence indicates a role for LHX3 in the specification of interneuron 
and ventral motor neuron fates during development (Sharma, Sheng et al. 1998). 
 
1.5 Diseases Associated With Mutations Within the LHX3 Gene 
The human LHX3 gene contains seven coding exons with six introns, and maps to 
chromosome 9 at 9q34.3 (Sloop, Showalter et al. 2000; Sloop, Walvoord et al. 2000). Ten 
autosomal recessive mutations within the human LHX3 gene have been reported thus far. 
These include missense mutations, intragenic deletions, nonsense mutations, and a 
complete gene deletion (Table 1.2). In accordance with observations of the Lhx3 
knockout mice, human patients with mutations in LHX3 present with deficiencies in GH, 
TSH, LH, FSH, and PRL hormones, and are diagnosed with CPHD (Netchine, Sobrier et 
al. 2000; Bhangoo, Hunter et al. 2006; Pfaeffle, Savage et al. 2007; Rajab, Kelberman et 
al. 2008; Kristrom, Zdunek et al. 2009). MRI analyses demonstrate variable pituitary 
morphology in patients with LHX3 mutations with some patients having hypoplastic 
pituitaries, others having enlarged pituitaries, and still others having normal pituitary 
morphology. In addition to CPHD, almost all mutations in LHX3 cause patients to present 
with a rigid cervical spine resulting in limited head rotation. This phenotype is 
presumably due to the role of LHX3 in spinal cord motor neuron specification. In mice, 
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Lhx3 expression has been shown to play a role in directing spinal motor neuron axon 
projections to the ventral side of the neural tube (Sharma, Sheng et al. 1998; Thaler, Lee 
et al. 2002). A subset of patients with LHX3 mutations have also been diagnosed with 
some form of mental deficiency (reviewed by Colvin, Mullen et al. 2009; Kristrom, 
Zdunek et al. 2009). More recently, Rajab et al. (2008) have published reports on two 
new mutations (p.K50X and an intragenic deletion) that extend the phenotype associated 
with mutations within the LHX3 gene (Rajab, Kelberman et al. 2008). These patients 
present with ACTH deficiency in addition to loss of the other anterior pituitary hormones, 
and they were found to exhibit sensorineural hearing loss ranging from mild/moderate to 
complete deafness. The same group also reported this sensorineural hearing loss in the 
patients with the p.Y111C and 23 bp deletion mutations originally described by Netchine 
et al (2000). The authors also found LHX3 to be expressed in the developing human inner 
ear supporting a role for LHX3 in ear development (Rajab, Kelberman et al. 2008). 
Future studies will help determine whether ACTH deficiency and hearing loss are 
common or more variable features associated with mutations within the LHX3 gene. 
Treatment for the endocrine symptoms of these patients involves hormone replacement 
therapy, including recombinant GH, T4, and gonadotropin therapy. Family members 
heterozygous for the LHX3 mutations are asymptomatic, which agrees with Lhx3+/- mice 
(reviewed by Colvin, Mullen et al. 2009).  
The position of most of the described mutations lies within the region of the gene 
that encodes the LIM domains or the homeodomain of the protein, thereby causing 
structural abnormalities within the protein (Table 1.2). Several described mutations are 
expected to result in no production of any LHX3 proteins. Other mutations may result in 
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the production of severely truncated proteins or messenger RNA transcripts that could be 
targets of nonsense-mediated decay resulting in the loss of LHX3 protein. Molecular 
analyses done with the predicted aberrant proteins of some of the more subtle LHX3 gene 
mutations show that LHX3 protein function is disabled or reduced if the protein is 
produced at all (Sloop, Parker et al. 2001; Savage, Hunter et al. 2007; Colvin, Mullen et 
al. 2009).  
 Of the 10 types of LHX3 mutation described to date, one mutation type (W224ter) 
does not result in the limited head rotation, defining a new form of the disease. This 
mutation, found in four siblings from a consanguineous Lebanese couple, is a guanine to 
adenine substitution at position 672 of the LHX3a ORF within exon 5 of the LHX3 gene. 
This substitution introduces a premature stop codon predicted to cause loss of the 
carboxyl terminus of the LHX3 protein (W224ter) (Pfaeffle, Savage et al. 2007). 
Functional tests with this protein showed that while it did not retain its ability to activate 
the GSU promoter, there was a synergistic effect with PIT1 on the PRL promoter in 
293T cells, although it was reduced. This protein also displayed reduced DNA binding 
ability, indicating that it may retain some continuing function in the pituitary (Pfaeffle, 
Savage et al. 2007). The endocrine phenotype of these patients seemed consistent with 
these results because although they were diagnosed with CPHD, they were not diagnosed 
until the ages of 14 and 15 years, indicating that there may have been some lingering 
pituitary function that decreased with time. At the ages of 9 and 8 years, they were 
diagnosed with secondary hypothyroidism and thyroxine replacement was initiated. 
However, the thyroxine replacement apparently had no significant impact on their height 
velocity because at 14 and 15 years of age, they presented with growth failure, and were 
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finally tested and diagnosed with CPHD (Pfaeffle, Savage et al. 2007). However, unlike 
the other patients with LHX3 mutations, these patients were unique in that they did not 
present with limited head rotation, indicating that not all LHX3 mutations are associated 
with a rigid cervical spine, and MRI analyses showed these patients had pituitaries of 
normal size and location.  
This study and these experiments provide us with a lot of information as to how 
this LHX3 mutation could be causing these patients’ CPHD. However, there are 
limitations to this type of study; mainly, that we are unable to directly examine these 
patients’ LHX3 proteins, thereby limiting our understanding of the mechanism of LHX3 
in development. It is possible that the premature termination codon of this mRNA in vivo 
could result in its degradation via nonsense-mediated decay resulting in no LHX3 
protein, although the delayed phenotype of these patients suggests that some LHX3 
function is retained. LHX3 plays an important role in the development of ventral motor 
neurons in the spinal cord. Previous work indicates that the LIM domains and 
homeodomain of LHX3 are required for the formation of a multiprotein complex 
necessary for spinal cord motor neuron development (Sharma, Sheng et al. 1998; Thor, 
Andersson et al. 1999; Thaler, Lee et al. 2002). Although the carboxyl terminus of LHX3 
contains the major trans-activation domain of the protein that could allow regulation of 
LHX3 function and location through signaling pathways, the LIM domains also appear to 
contain some activation function that may serve a role in the nervous system (Parker, 
Sandoval et al. 2000; Sloop, Showalter et al. 2000; Rhodes, Kator et al. 2005). For the 
patients with the W224ter mutation, the intact LIM domains and homeodomain may be 
sufficient for nervous system and some pituitary development, which would explain the 
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absence of limited neck rotation and abnormal pituitary morphology. However, although 
it is less severe and its development somewhat retarded, these patients with W224ter 
mutations still present with pituitary insufficiency demonstrating the importance of the 
carboxyl terminus in overall pituitary function. Our laboratory has been investigating the 
molecular functions of the carboxyl terminus of LHX3 and found this region to contain 
critical activation/repression domains, targets for post-translational modification, and 
intracellular targeting signals (Parker, Sandoval et al. 2000; Sloop, Showalter et al. 2000; 
Sloop, Dwyer et al. 2001; Parker, West et al. 2005; Savage, Hunter et al. 2007). The 
milder phenotype of these patients with later onset of hormone deficiency, normal 
pituitary morphology, and the absence of the limited neck rotation suggests that the 
actions of LHX3 in the pituitary and nervous system are separable, perhaps mediated by 
the different functional domains/motifs of the protein, and that the carboxyl terminus of 
LHX3 is essential for pituitary development. A knock-in mouse model of this human 
disease was generated to investigate the effects of this particular mutation throughout 
development at the molecular and cellular level, which is not feasible with human 
patients.  
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Figure 1.1. Development of the anterior pituitary gland within mammals. A. Inductive 
signaling between and within the ventral diencephalon (DIEN) of the brain and oral 
ectoderm/anterior neural ridge (OE/ANR) promotes the formation of a rudimentary 
Rathke's pouch (rRP), and the infundibulum (INF), from which the adenohypophysis and 
neurohypophysis will later develop, respectively. Later, a definitive Rathke's pouch 
(dRP) forms which then separates from the oral cavity. The mature pituitary gland is 
encased by the sella turcica (ST) of the sphenoid bone (SB). AP = anterior pituitary lobe, 
asterisk = intermediate pituitary lobe, IIIv = third ventricle of the brain, me = median 
eminence, PP = posterior pituitary, pt = pars tuberalis.  B. The five anterior pituitary 
hormone-secreting cell types, their hormone products, and the target organs of the 
hormones are shown. The receptors that allow regulation of pituitary hormone secretion 
by hypothalamic and other regulatory hormones are also depicted. ACT = activin, AVP = 
arginine vasopressin, CRH = corticotropin-releasing hormone, DA = dopamine, GHRH = 
growth hormone releasing hormone, GHS = growth hormone secretagogue/ghrelin, 
GnRH = gonadotropin-releasing hormone, LIF = leukemia inhibitory factor, OT = 
oxytocin, PACAP = pituitary adenylate cyclase-activating polypeptide, PRH = prolactin 
releasing hormone, SS = somatostatin, TRH = thyrotropin-releasing hormone, VIP = 
vasoactive intestinal peptide. Adapted from  Savage, Yaden et al. 2003. 
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Figure 1.2. Transcriptional regulation of anterior pituitary development. Inductive 
signaling events between the ventral diencephalon and the oral ectoderm promote the 
formation of a rudimentary Rathke’s pouch (RP). At the same time, these inductive 
signaling events initiate the expression of a cascade of transcription factors that guide the 
development of the specialized hormone-secreting cell types of the anterior pituitary. 
Adapted from Colvin, Mullen et al. 2009. 
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Table 1.1 Mutations within the LHX4 gene associated with combined pituitary hormone 
deficiency diseases. The diagram depicts the locations of the changes encoded by the 
mutations relative to the LHX4 mRNA. The positions of the sequences that encode the 
LIM domains and the homeodomain (HD) are indicated by the boxes. The numbering 
scheme for the LHX4 protein represented here begins with the first in-frame methionine 
in the human sequence: the p.P389T mutation in the table is therefore the same as the 
p.P366T mutation (Tajima, Hattori et al. 2007). Adapted from Colvin, Mullen et al. 2009.  
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Table 1.2. Mutations within the LHX3 gene associated with pediatric combined pituitary 
hormone deficiency diseases. The diagram depicts the locations of the molecular changes 
encoded by the mutations relative to the LHX3a mRNA. The positions of the sequences 
that encode the LIM domains and the homeodomain (HD) are indicated by the boxes. 
The extended horizontal lines ending in diamond symbols denote predicted alterations in 
protein reading frames ending in premature termination of translation. Adapted from 
Colvin, Mullen et al. 2009. 
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CHAPTER TWO 
 
MATERIALS AND METHODS 
 
 
 
2.1 DNA Cloning and Gene Targeting Vector Construction 
 
 
 
Mouse embryonic stem cell targeting 
Mouse genomic DNA of the 129/Sv strain was obtained as a gift from Emily 
Blue, P.A. Gallagher Laboratory, Cellular and Integrative Physiology, Indiana School of 
Medicine (IUSM), Indianapolis, IN. Approximately 5 kb of murine genomic Lhx3 was 
used for the homology arms and was generated using Pfu UltraII DNA polymerase 
(Stratagene, La Jolla, CA), the forward primer 5′-atggtttatgggatgggttacccg-3′, and the 
reverse primer 5′-aaccaacaggtagccaagatcctg-3′. Touchdown PCR parameters were used 
as follows: 95°C 5 min; 95°C 20 sec, 67°C 20 sec, 72°C 5 min 30 sec for 2 cycles; 95°C 
20 sec, 65°C 20 sec, 72°C 5 min 30 sec for 2 cycles; 95°C 20 sec, 63°C 20 sec, 72°C 5 
min 30 sec for 2 cycles; 95°C 20 sec, 61.5°C 20 sec, 72°C 5 min 30 sec for 2 cycles; and 
95°C 20 sec, 60°C 20 sec, 72°C 5 min 30 sec for 25 cycles. This reaction product was 
then cloned into the StrataClone PCR Cloning Vector using the StrataClone Blunt PCR 
Cloning Kit (Stratagene), and the W227ter mutation was introduced using site-directed 
mutagenesis (QuickChange II kit, Stratagene) and the following primers:  
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5′-cgctggccggcagcgctgaggacagtatttccgc-3′ and 5′-gcggaaatactgtcctcagcgctgccggccagcg-3′ 
(Figure 2.1A). Further manipulation required cloning the 5′ and 3′ homology arms into 
the PGK-neolox-2DTA vector, which was obtained as a gift from Dr. Stephen 
Konieczny, Ph.D., Purdue University, West Lafayette, IN. To clone the 2.9 kb 5′ 
homology arm, the StrataClone vector containing the 5 kb of murine genomic Lhx3 was 
first digested with HindIII and BspEI restriction enzymes (Figure 2.1A). The resulting 
sticky ends were then blunted using the Klenow enzyme (New England Biolabs, Ipswich, 
MA), and the 5′ arm was isolated by agarose gel electrophoresis and purified using 
Qiaquick gel extraction columns (Qiagen, Valencia, CA). The PGK-neolox-2DTA vector 
was first digested with NotI (Figure 2.1B), the sticky ends were blunted with Klenow 
enzyme (New England Biolabs), and the vector was then treated with calf intestinal 
alkaline phosphatase (CIAP). The 5′ arm was then ligated into the PGK-neolox-2DTA 
vector, and its presence was confirmed through a series of test digests and DNA 
sequencing. To clone the 2.2 kb 3′ arm, the StrataClone vector containing the 5 kb of 
murine genomic Lhx3 was digested with the BspEI restriction enzyme (Figure 2.1A). The 
resulting sticky ends were then blunted using the Klenow enzyme (New England 
Biolabs). This product was then HindIII digested, and the 3′ arm was isolated by agarose 
gel electrophoresis and purified using the Qiaquick gel extraction columns (Qiagen). The 
3′ arm was ligated into a HindIII site within the PGK-neolox-2DTA vector containing the 
5′ arm that had been previously digested (Figure 2.1B). The integrity of this construct 
was confirmed through a series of test digests and DNA sequencing.  
The gene targeting vector plasmid was purified via CsCl preparation, linearized 
by KpnI digestion, and two 50-µg aliquots at 1 µg/µl were submitted to the Transgenic 
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and Knock-Out Mouse Core of the IUSM for transfection into CCE 916 embryonic stem 
(ES) cells originally derived from a 129SvEv mouse. Twenty-five micrograms of 
linearized construct was electroporated into 10 million cells. The cells were then plated at 
one million cells per 10 cm plate, and G418 selection was started 48 hours post 
electroporation at 600 µg/ml. G418, or Geneticin, is an aminoglycoside antibiotic 
produced by Micromonospora rhodorangea which functions to block protein synthesis 
through interference with the 80S subunit of the ribosome. The Neomycin resistance 
(NeoR) gene provides resistance to G418 by encoding an aminoglycoside 3′-
phosphotransferase, APH 3′ II, which inhibits the function of G418. Four days after 
electroporation, the G418 selection was lowered to 300 µg/ml and maintained for 10 to 
12 days. Individual ES cells were picked 10 days after electroporation and expanded on 
24-well plates for a few days. After expansion, a portion of the cells were frozen for later 
use and the remaining cells were expanded on 24 well plates for screening. To screen the 
cells, the cell culture medium was removed and 600 µl of cell lysis solution (Qiagen) was 
added per well followed by a 2-3 hour incubation at 37°C. The ES cell lysates were then 
transferred to labeled microcentrifuge tubes for future screening. Of 191 129/Sv G418-
resistant ES cell clones received from the core, five were found to be positive via PCR 
and Southern blotting for both the Neo cassette and the point mutation and negative for 
the DTA cassette. After screening, the cells were expanded into injection stocks and 15 to 
18 cells were injected into 3.5 dpc C57BL/6J blastocysts. The blastocysts were then 
transferred to 2.5 dpc pseudopregnant Swiss Webster female mice, and resulting high 
percentage male chimeras were bred to C57BL/6J females to generate heterozygous 
mice.  
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DNA sequencing 
DNA sequencing was performed at the Biochemistry Biotechnology Facility at 
the Indiana School of Medicine using a PerkinElmer DNA sequencer. The DNA 
templates were submitted using the recommended guidelines from the sequencing 
facility, and the sequence analyses and assembly were performed using the DNASIS 
(Hitachi Software Engineering, San Francisco, CA) software.  
 
2.2 Identification of Homologous Recombinants 
 
PCR 
Genomic DNA was obtained from ES cell lysates by adding 4 µl of RNase A 
solution (4 mg/ml) to 600 µl ES cell lysate. The RNase A was mixed with the ES cell 
lysates by inverting the tubes 25 times and the tubes were then incubated at 37°C for 45 
minutes. Following this incubation, the samples were allowed to cool to room 
temperature for 15 minutes before 265 µl of protein precipitation solution (Qiagen) was 
added to the lysates. The lysates were then vortexed vigorously for 20 seconds followed 
by centrifugation at 13,000 rpm for 10 minutes. Supernatant containing the DNA was 
then poured into a clean 2.0 ml microcentrifuge tube and 800 µl isopropanol was added. 
The samples were mixed by inverting 50 times before centrifuging at 13,000 rpm for 5 
minutes to pellet the DNA. After centrifugation, the ethanol was poured off the pellet and 
800 µl 70% ethanol was added. The tubes were then inverted several times to wash the 
pellet before centrifuged at 13,000 rpm for 1 minute. The ethanol was poured off and the 
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pellets were allowed to air dry for 10-15 minutes before being resuspended in 100 µl TE 
buffer (20 mM Tris, 1 mM EDTA). DNA was stored at –20°C until ready for use.  
Genomic DNA from ES cell lysates received from the core was initially analyzed 
via PCR for the presence of the point mutation and the “Neo” cassette using FastStart 
HiFi Taq polymerase (Roche, Indianapolis, IN) and the following oligonucleotides: 5′-
tggacatgcgagtggtgcaggtca-3′, 5′-aaccaacaggtagccaagatcctg-3′. The PCR parameters were 
95°C 5 min.; 95°C 30 sec, 60°C 30 sec, and 72°C 2:20 min for 30 cycles. The resulting 
product was then digested with BbvCI enzyme to verify the presence of the point 
mutation in a heterozygous state with expected band sizes of 1,430 bp, 1,280 bp, 620 bp, 
and 150 bp if the point mutation was present, and 1,430 bp and 620 bp if the point 
mutation was not present. The absence of the DTA cassette was also confirmed through 
PCR using GoTaq polymerase (Promega, Madison, WI), the primers 5′-
aaggcgtagcctctaaatgcgaga-3′ and 5′-caacatcatcaggatccatggcga-3′, and the following PCR 
parameters: 95°C 5 min; 95°C 30 sec, 60°C 30 sec, and 72°C 45 sec for 30 cycles; the 
expected product size if the DTA cassette was present was 750 bp. 
Five ES cell lysates were positive for the point mutation and the Neo cassette and 
negative for the DTA cassette. Southern blotting was then used to screen genomic DNA 
from these five ES cell lysates and toe biopsies from the first set of heterozygous mice 
produced at the core facility to confirm the presence of the endogenous and targeted 
alleles. The probe used was located within the Lhx3 gene just downstream of the 3′ 
homology arm and was amplified using the primers 5′-caggatcttggctacctgttggtt-3′ and 5′-
acttgctcatccctcataccagca-3′, and the following PCR parameters: 95°C 5 min; 95°C 30 sec, 
60°C 30 sec, and 72°C 45 sec for 30 cycles; the expected product size was 720 bp. A vial 
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of frozen ES cells from each of the five positive ES cell lysates was sent to the Purdue 
University Cancer Center Transgenic Mouse Core Facility for chromosome counting. Of 
the number of cells counted within each lysate submitted, 70% of those cells needed to 
have a normal chromosome complement (40 chromosomes) to be considered acceptable 
for chimera production. Four of the five ES cell vials submitted fit these guidelines and 
were considered appropriate for blastocyst injection and chimera production.  
 
Southern blot 
Ten micrograms of DNA prepared from ES cell lysates as mentioned above was 
precipitated with 1 ml 100% EtOH and centrifuged at 13,000 rpm for 2 min. The pellet 
was then washed with 1 ml of 70% EtOH. After a quick spin down, the EtOH was 
removed and the pellet was allowed to air dry before being resuspended in 20 µl sterile 
water. After the DNA was digested with BamHI overnight, the DNA fragments were 
separated on a 0.8% agarose/1× Tris-Acetate gel in 1×TAE (40 mM Tris, 0.1142% 
glacial acetic acid, 2 mM EDTA) running buffer at 30 volts overnight. The gel was then 
stained with 0.5 µg/ml ethidium bromide for 20 min, and a picture of the gel was taken 
with a rule placed next to it for future orientation. Once excess gel had been trimmed off, 
the gel was depurinated in a 1:50 dilution of 32-38% HCl for 15 min, neutralized in 0.4 N 
NaOH for 15 min, and transferred overnight onto a Hybond-XL charged nylon membrane 
(GE Healthcare, Piscataway, NJ) that had been pre-soaked in 0.4 N NaOH. The next 
morning, the membrane was neutralized in 100 ml neutralization buffer (SSPE [0.15M 
NaCl, 10 mM NaH2PO4, 1.25 mM EDTA], 1M Tris pH 7.5) for 15 min, then pre-
hybridized with FBI buffer (SSPE [0.225M NaCl, 0.1M NaH2PO4, 1.875 mM EDTA], 
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10% PEG 8000, 7% SDS) at 65°C for 4 hours. During this time, fresh probe was made 
using the DECAprime II Random Primed DNA Labeling Kit (Ambion, Austin, TX) 
according to manufacturer’s instructions. Unincorporated 32P-labeled nucleotides were 
removed using illustra ProbeQuant G-50 Micro Columns (GE Healthcare). Radiolabeled 
probe was then counted and 1.5 × 106 cpm/ml denatured probe in 20 ml FBI buffer was 
allowed to hybridize with the membrane at 65°C overnight in a roller bottle at 4 rpm. The 
next day, the membrane was washed twice in 20 ml 1 × SSPE, 1% SDS for 15 min each 
wash at 65°C. The third wash was done at room temperature with 100 ml 1 × SSPE, 1% 
SDS for 15 min. The membrane was then exposed to Kodak BioMax MR film 
(Carestream Health, Inc., Rochester, NY) with an intensifying screen and stored at –80°C 
overnight before analysis.  
 
2.3 Genotyping and Breeding of Knock-In Mice 
Wild-type C57BL/6J female mice (The Jackson Laboratory, Bar Harbor, ME) 
were bred to male chimeras at the core facility to generate F1 heterozygote mice. 
Genomic DNA from tail biopsies from these heterozygotes was screened via PCR and 
Southern blot for the presence of the point mutation (see above). Of these heterozygotes, 
the males were transferred from the core to the LARC animal facility for further analyses. 
The female heterozygotes at the core were bred to male B6.FVB-Tg(EIIa-
Cre)C5379Lmgd/J mice (The Jackson Laboratory). This mouse line contains a Cre 
transgene paired with the adenovirus EIIa promoter to target the expression of Cre 
recombinase in the early mouse embryo and was used to promote the excision of the Neo 
cassette from the Lhx3 gene locus. Progeny from this cross were transferred to the LARC 
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animal facility and screened via PCR with GoTaq polymerase (Promega) and primers 
flanking the Neo cassette: 5′-aggttgcccgctttgagagaatta-3′ and 5′-tgacctgcaccactcgcatgtcca-
3′. The PCR parameters used were 95°C 5 min; 95°C 30 sec, 60°C 30 sec, and 72°C 2:20 
min for 30 cycles. The products generated from this PCR were used to genotype the 
animals: if the Neo cassette was still present, the expected band size was 2,270 bp, if the 
Neo cassette had been excised, the expected band size was 630 bp, and the expected band 
size for wild-type Lhx3 was 470 bp. Genomic DNA obtained from tail biopsies of 
weanlings was also screened for the presence of Cre recombinase using GoTaq 
polymerase (Promega), the forward primer 5′-ccaatttactgaccgtacacc-3′, the reverse primer 
5′-gtacgtgagatatctttaaccctgat-3′, and the following PCR parameters: 95°C 5 min; 95°C 30 
sec, 60°C 30 sec, and 72°C 30 sec for 30 cycles. If Cre recombinase was present, the 
expected band size was approximately 500 bp.  
Mice were housed in a specific pathogen-free environment under controlled 
conditions of temperature and light (12 hours lights on/12 hours lights off), and were 
provided free access to tap water and commercial mouse chow. Some homozygote dwarf 
mice were provided with daily wet feed on the bottom of the cage due to their small size. 
The Indiana University Committee on Use and Care of Animals approved all procedures 
done using the mice, and all experiments were performed in agreement with the 
principles and procedures outlined in the National Institutes of Health Guidelines for the 
Care and Use of Experimental Animals. Mouse age was designated such that the morning 
after conception was embryonic day 0.5 (e0.5) and the day of birth was postnatal day 1 
(P1).  
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Breeding into specific mouse strains 
All animal analyses were done on progeny of an N2 intercross with a mixed 
background of approximately 75% C57BL/6J and 25% 129/Sv. Fertility studies were 
carried out so that wild-type, heterozygote, and homozygote mice were housed as single 
breeding pairs for at least 4 months while fecundity was measured. The frequency of 
birth, number of offspring, and genotype were recorded. Mice also are being bred with 
wild-type C57BL/6J and 129/Sv (The Jackson Laboratory) for six generations to analyze 
the dwarf phenotype on each of these backgrounds. 
 
2.4 Histology and Immunohistochemistry 
Harvested tissues were fixed in 4% paraformaldehyde in 1 × phosphate buffered 
saline (PBS [137 mM NaCl, 5.4 mM KCl, 16.2 mM Na2HPO4, 2.9 mM KH2PO4]) for 1 
to 24 hours at room temperature. Fixed P1 neonates were washed in 1× PBS, dehydrated, 
and embedded in paraffin. Whole pituitaries from adult 12 week old animals were 
washed in 1× PBS, set in 20% sucrose in PBS overnight, embedded in O.C.T. compound 
(Sakura Finetek, Torrence, CA), and stored at –80°C for future cryosectioning. Paraffin-
embedded and frozen tissues were all cut at 10 µm and all sections were rehydrated, and 
antigen unmasked (boiled in 10 mM citric acid at pH 6.0 for 10 min) before 
immunostaining. Paraffin sections were deparaffinized through several xylene washes 
prior to rehydration and antigen unmasking.  
Both frozen and paraffin sections were immunostained using polyclonal 
antibodies for human ACTH (1:1,000 diaminobenzidine [DAB]; Sigma, St. Louis, MO) 
or (1:500 Fluor.) (AFP-39032082), rat αGSU (1:500 DAB) or (1:100 Fluor.) (AFP-
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66P9986), rat GH (1:1000 DAB) or (1:500 Fluor.) (AFP-5672099), rat LH (1:800 DAB) 
or (1:400 Fluor.) (AFP-571292393), rat TSH (1:1000 DAB) or (1:500 Fluor.) (AFP-
1274789), mouse PRL (1:100 Fluor.) (AFP-131078) (National Hormone and Pituitary 
Program, Torrance, CA), and mouse LIM-3 (1:1000 DAB) (Chemicon, Temecula, CA). 
Biotinylated secondary antibody was used with avidin and biotinylated peroxidase or 
fluorescent avidin alone (Vectastain rabbit kit; Vector Laboratories, Burlingame, CA). 
The chromogen DAB was used for some immunostaining reactions. 
 
2.5 RNA Analyses 
 
RNA extraction/cDNA synthesis 
 Mouse pituitaries from juvenile 6 week old animals and adult 12 week old 
animals were harvested and immediately placed in RNAlater solution (Ambion). RNA 
was isolated according to manufacturer’s instructions using an RNeasy Mini Kit 
(Qiagen), and pituitaries were homogenized using 1-ml 25G5/8 syringes (Becton 
Dickinson, Franklin Lakes, NJ). An on-column DNase I digestion was performed as 
suggested in the protocol (Qiagen). cDNA was synthesized using Multiscribe reverse 
transcriptase (RT) and random primers according to the protocol within the High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). 
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Quantitative PCR analyses 
 cDNA reverse transcription (RT) reactions were carried out in triplicate as 
described (see above). Negative control reactions that contained no RT enzyme were also 
performed. The relative abundance of the genes of interest was determined using real-
time quantitative PCR with the 5′ fluorogenic nuclease assay and an ABI 7900 PRISM 
(Applied Biosystems). The 5′ terminus of the fluorogenic probes was labeled with 6-
carboxy-fluorescein. The 3′ terminus of the 36B4 probe contained a non-fluorescent 
quencher—black-hole quencher-1 (Biosearch Technologies, Inc., Novato, CA). Primer 
and probe sequences were as follows: 36B4 forward primer, 5′-ggcccgagaagacctcctt-3′, 
36B4 reverse primer, 5′-tcaatggtgcctctggagatt-3′, and 36B4 TaqMan probe, 5′-
ccaggctttgggcatcaccacg-3′. The Lhx3a (Mm00521922_m1), Lhx3b (Mm01333633_m1), 
Lhx3a & b (Mm01330618_g1), Lhx4 (Mm00521928_m1), Gh (Mm00433590_g1), Fsh 
(Mm00433361_m1), Pou1f1 (Mm00476852_m1), Tsh (Mm00437190_m1), Pomc 
(Mm00435874_m1), Prl (Mm00599949_m1), Gsu (Mm00438189_m1), Pitx1 
(Mm00440824_m1), Lh (Mm00656868_g1), and Gnrhr (Mm00439143_m1) primers 
and probes were synthesized by Applied Biosystems, and the 3′ terminus of these probes 
contained the quenching molecule minor-groove binder (MGB). PCRs were run in 
triplicate 20 µl reactions that contained Universal Master Mix (Applied Biosystems), 10 
pmol of each forward and reverse primer, 3.5 pmol probe, and 4 µl diluted cDNA from 
the RT reactions. The two-step PCR cycling parameters were as follows: 50°C 2 min for 
one cycle, 95°C 10 min for one cycle, and 95°C 15 sec and 60°C 1 min for 40 cycles. 
Data were normalized by determining the relative abundance of 36B4 mRNA. The 36B4 
gene encodes an acidic ribosomal phosphoprotein P0 (RPLP0). This phosphoprotein 
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associates tightly with the smaller 40S subunit of the ribosome. The 5′ open reading 
frame of 36B4 cDNA is highly conserved across tissues and species, and therefore, it is 
used frequently as a reference gene for normalizing data in real-time quantitative PCR 
assays. To allow for better comparison between groups at the different time points 
examined, wild-type data were normalized to 1 and heterozygote and homozygote data 
were subsequently adjusted.  
 
2.6 Microscopy 
 Fluorescent images were obtained with a Nikon Eclipse 90i microscope (Nikon 
Instruments, Inc., Melville, NY) with DAPI, FITC, and TRITC filter cubes. Canvas 
(ACD Systems of America, Inc., Miami, FL) and NIS Elements (Nikon Instruments, Inc.) 
were used to process the images. Light images of whole pituitaries were obtained using a 
Leica MZ 6 microscope and a CCD camera (PL A662, PixeLINK, Ottawa, Ontario, 
Canada) with PixeLINK Capture software.  
 
2.7 Hormone Analyses 
 
Sera collection 
Trunk blood was taken after decapitation and placed in 1.5 ml snap-cap 
polypropylene microcentrifuge tubes containing 100 µl heparin (Baxter Healthcare 
Corporation, Deerfield, IL). The samples were then spun down at 5,000 rpm for 10 min at 
4°C after which sera was collected and placed in a new 1.5 ml microcentrifuge tube. The 
sera samples were then stored at –20°C in a non-frost freezer until hormone analyses 
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could be performed. Enzyme-linked immunosorbent assays (ELISA), or enzyme 
immunoassays (EIA), were used to analyze levels of mouse insulin-like growth factor 1 
(IGF-1) (Immunodiagnostic Systems, Scottsdale, AZ, AC-42F1), human T4 (thyroxine) 
(ALPCO, Salem, NH, 25-TT4HU-EO1), human testosterone (DRG International, Inc., 
Mountainside, NJ, EIA-1559), and mouse/rat prolactin (Calbiotech, Spring Valley, CA, 
PR063F-100) hormone levels within the mouse serum according to the manufacturer’s 
instructions for each kit.  
 
Western blotting 
Pituitaries from adult 12 week old animals were lysed in ice-cold RIPA Buffer 
(1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 0.15M NaCl, 0.01 M N3PO4, pH 7.2, 2 
mM EDTA and 50 mM NaFl ) supplemented with protease inhibitors (Sigma). The 
samples were sonicated at level 6 for 10 seconds and incubated on ice for 10 minutes. 
After the incubation, samples were centrifuged full speed for 3 minutes and the 
supernatant was stored at -80°C. The protein concentration was determined by Bradford 
assay.  
Harvested pituitary tissue (30 µg) was run at 100 V on a 12% acrylamide gel and 
transferred to a charged PVDF membrane in western transfer buffer (192 mM glycine, 2 
mM Tris, 20% methanol). The membrane was blocked in 5% nonfat dry milk (NFDM, 
Carnation) in TBST (Tris-Buffered Saline tween (154 mM NaCl, 52 mM Tris, 1% Tween 
20) with shaking. After blocking, the membrane was washed with TBST and incubated 
with primary antibodies LH (NHPP, 1:600) and PRL (Santa Cruz, 1:200) in TBST 
overnight at 4°C. The membrane was washed with TBST and then incubated with 
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peroxidase conjugated secondary antibody (1:25,000) in TBST for 1 hour. The membrane 
was then incubated in SuperSignal West Dura Extended Duration Substrate (Pierce) for 1 
minute with gentle mixing prior to exposure. (Western blot information written and 
obtained by Raleigh E. Malik).  
 
2.8 General Molecular Techniques 
 
Ligations and transformations 
 DNA fragments to be ligated were examined for size and abundance by agarose 
gel electrophoresis. DNA fragments were joined using 1 µl T4 DNA ligase (Roche) in a 
total volume of 15 µl buffered solution at 16°C overnight. Five µl of the ligation reaction 
or 2-5 ng of plasmid preparation were transformed into bacterial cells to generate clones. 
Plasmid DNA was then added to 50 µl of chemically competent E. coli DH5 cells 
(Invitrogen) on ice. This mixture was heat shocked at 42°C for 45 sec and placed on ice 
again for 2 min. Eight hundred microliters of LB broth supplemented with 0.2% glucose 
and 10 mM MgCl2 was added and this mixture was incubated at 37°C for 45-60 min with 
shaking at 150 rpm. After incubation, cultures were centrifuged at 2,400 × g for 2 min to 
pellet the cells. The supernatants were aspirated, and the remaining cells were 
resuspended in 200 µl fresh LB broth. Cell suspensions were plated on LB agar plates 
containing the appropriate selective antibiotic.  
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Small scale alkaline lysis plasmid preparation 
 E. coli DH5 transformants were incubated at 37°C overnight with shaking at 250 
rpm in LB broth with appropriate antibiotics. To pellet cells, 1.5 ml of liquid culture was 
centrifuged at 16,000 × g for 1 minute. After the supernatant was aspirated, the pellet was 
resuspended in 100 µl hypertonic solution 1 (50 mM Tris-HCl, pH 8.0, 0.9% glucose, 10 
mM EDTA) and allowed to incubate on ice for 5 minutes. The addition of 200 µl solution 
2 (0.2 M NaOH, 0.5% SDS) lysed the cells, and this was followed by gentle mixing and 
incubation on ice for 5 min. One hundred seventy-five microliters of solution 3 (3 M 
KOAc, 11.5% (v/v) glacial acetic acid) was added followed by an additional incubation 
on ice for 5 min before the solution was centrifuged at 16,000 × g for 10 min. After the 
addition of 300 µl of a 1:1 phenol/chloroform solution, the sample was then centrifuged 
at 16,000 × g for 10 min. The upper aqueous phase was carefully removed and placed in 
a new 1.5 ml microcentrifuge tube before the addition of 1 volume of room temperature 
isopropanol to precipitate nucleic acids. The sample was centrifuged at 16,000 × g for 10 
min and the pellet washed with 75% ethanol. The pellet was dried at 37°C for 5 min and 
resuspended in 30 µl TER (100 µg/ml RNaseA in 1 × TE buffer [10 mM Tris-Cl, pH 7.4, 
1 mM EDTA]).  
Between 2-5 μl of the plasmid preparations were digested with restriction 
endonucleases using the recommended buffer conditions (New England Biolabs). 
Restriction digests were separated on agarose/1× Tris-borate gels to select properly 
constructed plasmids. 
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Gel purification of DNA fragments 
 DNA fragments to be gel purified were separated on 0.7% or 1.0% agarose/Tris-
borate gels. Gel slices including the fragments of interest were excised using razor blades 
and long wavelength ultraviolet light. Gel purification was performed with regular 
Qiaquick or MinElute gel extraction columns (Qiagen) according to the manufacturer’s 
protocol. Elution from the column was performed with either 10 μl (MinElute) or 30 μl 
(Qiaquick) of the supplied buffer. 
 
2.9 Statistical Analyses 
 Quantitative PCR data and hormone data were analyzed using a two-tailed 
Student’s t-test for unpaired samples using Excel (Microsoft Corp., Redmond, VA). Data 
points from the homozygous Lhx3W227ter/W227ter knock-in animals were compared to data 
points obtained for the Lhx3+/+ wild-type control animals. The data were considered 
significantly different when P<0.05. Data used in the weight charts were analyzed using a 
one-way ANOVA to compare data points obtained for animals wild-type (+/+), 
heterozygous (+/W227ter), and homozygous (W227ter/W227ter) for the 
Lhx3W227ter/W227ter mutation. Tthe data were considered significantly different when 
P<0.05.  
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Figure 2.1. Generating the Targeting Construct. A. Five kilobases of mouse genomic 
Lhx3 was isolated via PCR and cloned into a StrataClone vector. The point mutation was 
introduced at the appropriate location within the gene using site-directed mutagenesis. B. 
Through a series of digests, the 5 kb of genomic Lhx3 within the StrataClone vector in 
panel A was split into two homology arms. The homology arms were then ligated into the 
PGKneolox2DTA vector as shown.  
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CHAPTER THREE 
 
A MOUSE MODEL OF HUMAN PEDIATRIC COMBINED PITUITARY HORMONE 
DEFICIENCY DISEASE 
 
 
 
3.1 Introduction 
 Patients with mutations within the LHX3 gene are diagnosed with CPHD and 
typically present with other syndromic features, including limited head rotation, in 
addition to pituitary hormone deficiencies. Patients with the LHX3W224ter mutation 
present with the expected hormone deficiencies, but they do not have the limited head 
rotation thereby defining a new form of the disease (Pfaeffle, Savage et al. 2007). The 
location of this particular mutation within the LHX3 protein is interesting in that it occurs 
just beyond the homeodomain and results in a truncated LHX3 protein that lacks the 
carboxyl terminus which has been shown to contain the critical activation domain 
necessary to activate pituitary target genes. Patient observation and molecular work done 
with this truncated protein suggest our hypothesis, which is that the actions of LHX3 
within the nervous system and pituitary appear to be separable in vivo with the carboxyl 
terminus of LHX3 being essential for the proper development of the anterior pituitary 
gland. 
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3.2 Results 
 
Generation of Lhx3W227ter/W227ter mice 
A knock-in mouse model of the human disease caused by the LHX3W224ter 
mutation was generated to investigate the effects of this particular mutation throughout 
development at the molecular and cellular level, an analysis which is not feasible with 
human patients. A targeting construct was generated and site-directed mutagenesis was 
used to introduce the point mutation at the appropriate place within the 129/Sv mouse 
Lhx3 gene (Figure 3.1A). While the conserved tryptophan is located at position 224 
within the human LHX3 protein sequence, the equivalent tryptophan within the mouse 
LHX3 protein sequence is at position 227. The introduction of this point mutation created 
a BbvCI restriction site and PCR, restriction digest, and Southern blotting were used to 
identify correctly targeted ES cells, and later, the genotype of the animals produced 
(Figure 3.1 A-D). Correctly targeted clones were injected into C57BL/6J blastocysts and 
the resulting male chimeras were bred to female C57BL/6J mice to generate F1 
heterozygotes. At this point, two different lines of mice were made: those that would 
retain the “Neo” cassette, and those that would have the “Neo” cassette removed from 
their Lhx3 genomic locus using Cre-lox technology. The F1 male heterozygotes were 
paired with female C57BL/6J mice to generate N2 heterozygotes that were intercrossed 
to produce Lhx3W227ter/W227ter mice that still retained the “Neo” cassette (+Neo animals). 
The F1 female heterozygotes were bred with male B6.FVB-Tg(EIIa-Cre)C5379Lmgd/J 
mice (The Jackson Laboratory) to generate N2 heterozygotes in which the “Neo” cassette 
had been excised. The EIIa-Cre gene is expressed ubiquitously within the mouse embryo 
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prior to its implantation within the uterine wall. These N2 heterozygotes were 
intercrossed to produce Lhx3W227ter/W227ter mice which lacked the “Neo” cassette (-Neo 
animals). Several litters produced by the (+Neo) animals did not yield any viable 
Lhx3W227ter/W227ter mice, thus this line was not maintained (Figure 3.1F). However, the (-
Neo) line of animals produced Lhx3W227ter/W227ter pups available for analyses. Since the 
Lhx3 locus of the (-Neo) animals was closest to its native form and to that of the human 
patients, this line of animals was continued and all experiments were performed on the 
offspring of the N2 intercross of mixed genetic background within the (-Neo) line of 
animals.  
 
Lhx3W227ter/W227ter mice survive and exhibit a dwarf phenotype 
 Wild-type, heterozygote, and homozygote animals were produced at the 
appropriate 1:2:1 Mendelian ratio with Lhx3+/W227ter heterozygotes appearing no different 
from their wild-type litter mates. Very little prenatal loss was observed, however, some 
postnatal loss was noted with several homozygote stillbirths (Figure 3.1F), and a few 
Lhx3W227ter/W227ter mice exhibited wasting and eventually died between the ages of P21 
and P60. Initially, Lhx3W227ter/W227ter homozygote mice resembled their heterozygote and 
wild-type counterparts, however, growth insufficiency was noticed as early as P10 with a 
significant difference in the size of the Lhx3W227ter/W227ter homozygote mice noted around 
P21 and continuing into adulthood (Figure 3.2). The anterior pituitary of adult 
Lhx3W227ter/W227ter mice is severely hypoplastic when compared to that of adult wild-type 
animals, while their posterior lobes appear to be similar in size (Figure 3.3A). To further 
examine the growth deficiency of the Lhx3W227ter/W227ter mice, immunohistochemical 
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staining (IHC) with hormone markers was done on pituitaries of mice at P1 and at 12 
weeks old. IHC staining shows that GH- and TSH-producing cells are reduced at P1 
(Figure 3.3B and D). The GH staining in the Lhx3W227ter/W227ter pituitaries at P1 varied 
with some mutant pituitaries exhibiting very little GH staining (inset picture of Figure 
3.3B). While there appears to be similar densities of GH-producing cells staining at 12 
weeks between the wild-type and the Lhx3W227ter/W227ter pituitaries, the mutant pituitaries 
are still hypoplastic (Figure 3.3C). TSH-positive cells are reduced at 12 weeks in the 
Lhx3W227ter/W227ter pituitaries (Figure 3.3E). Real-time quantitative PCR analyses revealed 
a deficiency in Gh transcript in Lhx3W227ter/W227ter mice at both 6 weeks of age (Figure 
3.3F) and at 12 weeks of age (Figure 3.3G), and a decrease in transcript levels for the 
alpha subunit of TSH (Gsu) was also seen at these time points (Figure 3.4A-B). 
However, Tshb transcript is increased at both 6 weeks of age (Figure 3.4C) and at 12 
weeks of age (Figure 3.4D) in the Lhx3W227ter/W227ter knock-in mice.  
Since pituitary GH acts on the liver to produce insulin-like growth factor 1 (IGF-
1), and pituitary TSH promotes the production of thyroxine (T4) from the thyroid, serum 
hormone levels of total IGF-1 and total T4 were measured in the mice at a 6 week time 
point (representing juvenile mice at a pubertal time point) and at a 12 week time point 
(representing adult mice finished with puberty). Serum IGF-1 levels are relatively similar 
to the Gh transcript levels. At the 6 week time point, both Gh transcript and IGF-1 
hormone levels are reduced significantly in Lhx3W227ter/W227ter mice (Figure 3.3F and 
3.3H). At the 12 week time point, Gh transcript and IGF-1 hormone levels are still lower 
in Lhx3W227ter/W227ter mice, but it is no longer significant (Figure 3.3G and 3.3I). Total T4 
was significantly lower at both time points in the Lhx3W227ter/W227ter mice (Figure 3.3J-K). 
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Histological examination of the thyroid glands of the mice showed reduced follicle size 
which is indicative of hypothyroidism (Figure 3.3L-M).  
 
Fertility is compromised in Lhx3W227ter/W227ter mice 
 Given the hormone deficiencies of the human patients, we expected similar 
hormone deficiencies in the Lhx3W227ter/W227ter mice, with LH, FSH, and PRL deficits 
possibly leading to reduced fertility. Test matings were set up with wild-type males 
paired with Lhx3W227ter/W227ter female mice, wild-type females paired with 
Lhx3W227ter/W227ter male mice, and male and female Lhx3+/W227ter heterozygote pairs were 
used as controls (Table 1). Over a four month period, the percentage of breeding pairs 
producing offspring (productive matings), the average number of litters produced, and the 
mean litter size were recorded so that relative fecundity (R.F.) could be calculated  as we 
have previously described (Savage, Mullen et al. 2007)(Silver 1995). The Lhx3+/W227ter 
heterozygote animals did not have any apparent reduction in fertility producing litters on 
average every 24 days (R.F. = 24.4). Of the control heterozygote crossings (n = 18) and 
the Lhx3W227ter/W227ter male mice paired with wild-type females (n = 10), 100% of those 
pairs produced litters. While the Lhx3W227ter/W227ter male mice were able to produce litters 
of comparable size to those mice of the heterozygote crossings, they produced litters at a 
reduced rate (R.F. = 18.5). The female Lhx3W227ter/W227ter mice paired with wild-type 
males (n = 9) never produced any litters (Table 1).  
To further examine the reduced fertility of the male Lhx3W227ter/W227ter mice and 
the infertility of the female Lhx3W227ter/W227ter mice, IHC staining at P1 and at 12 weeks of 
age of male and female Lhx3W227ter/W227ter pituitaries revealed deficiencies in LH- 
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(Figure 3.5A-B), and FSH-producing cells (data not shown). As with GH, variation was 
seen with the LH staining within the Lhx3W227ter/W227ter pituitaries at P1 with some 
mutant pituitaries displaying very little staining. Real time quantitative PCR analyses at 6 
weeks of age determined that the transcript levels of both Lhb (Figure 3.4E) and Fshb 
(Figure 3.4G) were not significantly different in the knock-in mice compared to the wild-
type and heterozygote controls. However, at 12 weeks of age, Lhb (Figure 3.4F) and Fshb 
(Figure 3.4H) transcript levels were both increased in the Lhx3W227ter/W227ter mice. And, as 
previously mentioned, transcript levels of the alpha subunit of both LH and FSH (Gsu) 
was down at both 6 weeks and 12 weeks of age (Figure 3.4A-B). Gnrhr transcript was 
also measured in the mice at 12 weeks of age, but no significant difference was observed 
in Gnrhr transcript levels between the Lhx3W227ter/W227ter mice and the wild-type and 
heterozygote controls (Figure 3.4I).  
The seminal vesicles of male Lhx3W227ter/W227ter mice are proportionally smaller 
than wild-type male mice at both 6 weeks of age (Figure 3.5C) and at 12 weeks of age 
(Figure 3.5D). Further analyses of juvenile males (6 weeks old) show a difference 
between the weights of the seminal vesicles of the male Lhx3W227ter/W227ter mice and those 
of wild-type controls, with the seminal vesicles of the mutant mice weighing significantly 
less. This is indicative of reduced testosterone production in the male Lhx3W227ter/W227ter 
mice. A reduction in the size of the prostate and testes of the male Lhx3W227ter/W227ter mice 
was also consistently noted, but was not significant compared to wild-type controls. 
Histological examination of the seminal vesicles (Figure 3.5G) and prostate (Figure 3.5I) 
showed reduced secretions in these structures of the male Lhx3W227ter/W227ter mice, while in 
the testes, spermatogenesis was either decreased or absent with no mature sperm apparent 
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within the testes (Figure 3.5H) or epididymis, implying sexual immaturity of the male 
Lhx3W227ter/W227ter mice at 6 weeks of age compared to wild-type controls. Ovarian failure 
does not appear to be the primary cause of the infertility noted in the female 
Lhx3W227ter/W227ter mice as the ovaries of the mutant mice appear to be functioning 
normally with corpora lutea present along with both mature and immature eggs similar to 
that observed in the wild-type females at 6 weeks of age (Figure 3.5G). However, a 
severe lack of PRL is evident in both male and female Lhx3W227ter/W227ter mice. IHC 
staining at both P1 and 12 weeks of age demonstrate a deficiency in PRL-producing 
lactotrope cells of the pituitaries of Lhx3W227ter/W227ter mice (Figure 3.6A-B). The Prl 
transcript is strikingly down in the pituitaries of Lhx3W227ter/W227ter mice at both 6 weeks 
(Figure 3.6C) and 12 weeks (Figure 3.6D) of age. Corresponding with the decrease in 
transcript level, PRL hormone levels are also down in the Lhx3W227ter/W227ter mice at these 
time points (Figure 3.6E-F). Western blot data confirm a near absence of PRL protein in 
the pituitaries of adult Lhx3W227ter/W227ter mice compared to wild-type controls (Figure 
3.6G) (western blot data obtained by Raleigh Malik). Histological examination of the 
uteri of female Lhx3W227ter/W227ter mice revealed a proportional significant difference in the 
weight and size, with the uteri of the Lhx3W227ter/W227ter mice weighing significantly less 
than those of wild-type females (Figure 3.5E). Closer examination revealed a more 
immature uterus of Lhx3W227ter/W227ter female mice compared to that of wild-type controls 
at 6 weeks of age (Figure 3.5F). In the wild-type females, the thickness and keratinization 
of the uterine wall changed with estrous; however, the uteri of the mutant female mice 
did not seem to reflect the varying stages of estrous. The uterine wall of the mutant 
female mice was thinner with no keratinization.  
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Other pituitary hormone analyses 
 In addition to the expected deficiencies in hormones in the knock-in mice, IHC 
staining in pituitaries of Lhx3W227ter/W227ter mice indicated that ACTH-positive cells were 
reduced in the knock-in mice at both P1 (Figure 3.7A) and at 12 weeks (Figure 3.7B). 
Pomc transcript levels were also decreased at 12 weeks although not significantly (Figure 
3.7C).    
  
Altered gene expression in Lhx3W227ter/W227ter mice 
 Real time qPCR analyses done at 12 weeks of age revealed a difference in gene 
expression of several different genes involved in pituitary development within the 
pituitaries of Lhx3W227ter/W227ter knock-in mice. Using a Taqman probe placed within the 
Lhx3 transcript so that both the Lhx3a and the Lhx3b transcripts would be measured, real-
time qPCR analyses demonstrated a significant decrease in Lhx3a&b transcript levels in 
the Lhx3W227ter/W227ter knock-in mice at both 6 weeks (Figure 3.8A) and 12 weeks (Figure 
3.8B) of age. Also, mice heterozygous for the knock-in mutation have reduced levels of 
Lhx3a&b transcript with this reduction significant at 6 weeks (Figure 3.8A). Lhx4 
transcript levels were also examined, but no significant difference was found between the 
knock-in mice and the wild-type and heterozygote controls (Figure 3.8E). Pit-1 transcript 
levels were significantly decreased in the Lhx3W227ter/W227ter knock-in mice (Figure 3.8C); 
however, Pitx1 transcript levels were significantly increased in pituitaries of 
Lhx3W227ter/W227ter knock-in mice (Figure 3.8D).  
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Table 3.1. Reproductive performance of Lhx3 W227ter mice. 
  Number 
of pairsa 
Average 
number 
of  
littersb 
Average 
litter 
size 
Relative 
fecundityc
+/W227ter males x  
+/W227ter females 
18  4.2±1  5.8±2.4  24.4 
W227ter/W227ter males x  
+/+ females 
10  2.8±1.1  6.6±2.0  18.5 
+/+ males x  
W227ter/W227ter females 
9  0  0  0 
 
aAll mice were maintained as breeding pairs for a minimum of four months.  
bAverage number of litters produced from breeding pairs paired together over a four 
month mating period. 
cRelative fecundity is calculated as (productive matings) x (litter size) x (number of 
litters) (Silver 1995).  
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Figure 3.1. Lhx3W227ter/W227ter mice are viable.  A. Strategy for knocking in the W227ter 
point mutation using homologous recombination. The wild-type Lhx3 allele, the targeting 
construct, the Lhx3 allele with the point mutation and LoxP-“Neo” cassette knocked in 
(Targeted Lhx3 + Neo), and the Lhx3 allele with the point mutation and after removal of 
the Neo cassette (Targeted Lhx3) are shown. Coding regions of Lhx3 exons are denoted 
by black boxes. The W227ter point mutation introduces a novel BbvCI restriction enzyme 
site used for genotyping. Predicted DNA fragments that hybridize with the indicated 
probe during Southern blot analysis are shown. Primers used for PCR analysis of 
genomic DNA obtained from ES cells and animals are represented as black arrowheads.  
B. Diagnostic PCR analysis demonstrates correct targeting of four representative ES cell 
lines. A 2750 kb fragment was amplified using the primers shown above and was then 
digested with the BbvCI to demonstrate the presence of both the Neo cassette and the 
point mutation.  C. Southern blot analysis using BamHI confirms the presence of both the 
wild-type Lhx3 allele (15 kb) and the targeted Lhx3 allele (4.9 kb).  D. PCR to confirm 
the generation of the expected genotypes. A 2050 kb fragment digested with BbvCI 
enzyme to confirm the presence of the point mutation. Littermates were either wild-type 
(+/+), heterozygous (+/K), or homozygous for the W227ter knock-in mutation (K/K).  E. 
Genotyping to confirm removal of the Neo cassette following crossing to Cre-expressing 
mice. Expected band sizes are 470 bp for wild-type and 630 bp for the knock-in.  F. 
Lhx3W227ter/W227ter mice are viable with almost no prenatal loss and little postnatal loss. By 
contrast, Lhx3W227ter/W227ter mice retaining Neo sequences have high rates of prenatal and 
postnatal death. Asterisk (*) indicates the number of mice viable at 2 weeks of age when 
genotyping occurred.  
 
58 
 
 
Figure 3.1 
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Figure 3.2. Lhx3W227ter/W227ter mice are dwarfed.  A-B. In comparison to wild-type and 
heterozygote controls, growth deficiency of both male (A) and female (B) 
Lhx3W227ter/W227ter mice is evident around postnatal day 10 (P10) and becomes significant 
at P21. Asterisks (*) indicate a significant difference between homozygote 
Lhx3W227ter/W227ter compared to wild-type and heterozygote controls with p<0.05. As it 
proved to be difficult to weigh the same population of animals at every time point 
examined, the depicted n values represent the minimum number of animals weighed at a 
given time point. C. The picture represents Lhx3+/+ (left) and Lhx3W227ter/W227ter male 
littermates at 8 weeks old. 
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Figure 3.2 
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Figure 3.3.  Deficiencies in the growth hormone and thyroid hormone pituitary signaling 
axes underlie dwarfism in Lhx3W227ter/W227ter mice.  A. The anterior lobe (AL) of 12 week 
old adult Lhx3W227ter/W227ter pituitary gland is hypoplastic compared that of wild- type 
(+/+) animals while the posterior lobes (PL, dotted oval) are of similar size. Scale bar = 1 
mm.  B-E. Immunostaining of P1 (B and D) and 12 week old pituitaries (C and E) 
reveals deficiencies in GH- and TSHβ-producing cells of the Lhx3W227ter/W227ter pituitaries. 
The inset in panel B shows an additional example of an Lhx3W227ter/W227ter animal with 
negligible GH-producing cells. Scale bars = 200 μm.  F-G. Real-time quantitative PCR 
analyses show that the Gh transcript is decreased in the Lhx3W227ter/W227ter mutant mice 
(KI/KI) at both 6 weeks (F) and 12 weeks (G) of age. Data are mRNA levels normalized 
to a control transcript (36b4).  H-K. Hormone analyses of trunk blood serum indicate a 
decrease in both IGF-1 and T4 levels in the Lhx3W227ter/W227ter mutant mice (KI/KI) 
compared to their wild type (+/+) and heterozygote (+/KI) counterparts at both 6 weeks 
(H and J) and 12 weeks (I and K) of age.  L-M. Thyroid follicles of Lhx3W227ter/W227ter 
mutant mice (M) are smaller compared to those of wild type mice (L) indicating impaired 
thyroid function. Scale bar = 50 μm. Asterisks (*) indicate significance when compared 
to wild type controls with p<0.05. 
 
62 
 
 
Figure 3.3 
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Figure 3.4. Altered expression of dimeric hormone transcripts. A-B. Real-time 
quantitative PCR analyses show that the αGsu (Cga) transcript is decreased in the 
Lhx3W227ter/W227ter mutant mice (KI/KI) at 6 weeks (A) and at 12 weeks (B) of age. 
However, the Tshb transcript is increased in the Lhx3W227ter/W227ter mutant mice (KI/KI) at 
both 6 weeks (C) and 12 weeks (D) of age. At 6 weeks of age, Lhb (E) and Fshb (G) 
transcript in the Lhx3W227ter/W227ter mutant mice (KI/KI) are not significantly different 
from wild-type (+/+) and heterozygote (+/KI) controls, but at the 12 week time point, 
both Lhb (F) and Fshb (H) transcript levels are significantly increased in the knock-in 
mice compared to wild-type controls. I. No significant difference in Gnrhr transcript 
levels was observed in the Lhx3W227ter/W227ter mutant mice (KI/KI) compared to wild-type 
(+/+) animals at 12 weeks of age. Asterisks (*) indicate significance when compared to 
wild type controls with p<0.05. 
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Figure 3.4 
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Figure 3.5. Sexual maturation and fertility are impaired in Lhx3W227ter/W227ter mice. A-B. 
Immunostaining reveals reduced numbers of LH-producing gonadotrope cells in 
pituitaries of Lhx3W227ter/W227ter mice at both P1 (A) and at 12 weeks (B). Scale bars = 200 
μm. C-D. Seminal vesicles in male Lhx3W227Ter/W227Ter mice are smaller than those of wild 
type male mice at both 6 weeks (C) and 12 weeks (D) of age. Scale bars = 0.5 cm. E. The 
uteri of female Lhx3W227ter/W227ter mutant mice are significantly smaller than wild-type 
controls at 6 weeks of age. Scale bar = 1 cm.  F-G. Histological examination indicates the 
uteri of female Lhx3W227ter/W227ter mutant mice are immature compared to wild-type 
controls (+/+) (F) while the ovaries of female Lhx3W227ter/W227ter mutant mice appear 
similar to wild-type controls (G). Scale bars = 100 μm.  H-J. Histological analyses of 
seminal vesicles (H), testes (I), and prostates (J) of Lhx3+/+ and Lhx3W227ter/W227ter male 
mice at 6 weeks of age indicate delayed sexual maturity of the Lhx3W227ter/W227ter mice 
compared to wild type (+/+)  controls. Scale bars = 100 μm.  
 
66 
 
 
Figure 3.5 
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Figure 3.6. PRL deficiency and infertility in Lhx3W227ter/W227ter female mice.  A-B. PRL 
immunostaining of pituitaries of P1 (A) and 12 week old (B) mice show a paucity of 
PRL-producing lactotrope cells in Lhx3W227ter/W227ter mice. Scale bars = 200 μm. C-D. 
Real-time quantitative PCR analyses demonstrate a striking reduction in Prl transcript in 
Lhx3W227ter/W227ter pituitaries (KI/KI) relative to their wild type (+/+) and heterozygote 
(+/KI) counterparts at both 6 weeks (C) and at 12 weeks (D) of age. Data are mRNA 
levels normalized to a control transcript (36b4).  E-F. Hormone analyses also show a 
dramatic decrease in serum PRL in Lhx3W227ter/W227ter mutant mice at both 6 weeks (E) 
and 12 weeks (F). Asterisk (*) indicates significance compared to wild type controls with 
p<0.05 or less. G. Western blot detection of PRL protein in pituitaries confirms the PRL 
deficiency in the Lhx3W227ter/W227ter mutant mice compared to wild type controls. Blots 
were reprobed with an anti-GAPDH antibody as a loading control.   
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Figure 3.6 
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Figure 3.7.  The corticotrope population is decreased in pituitaries of Lhx3W227ter/W227ter 
mice.  A-B. Immunostaining of P1 (A) and 12 week old pituitaries (B) reveals a 
deficiency in ACTH-producing cells of the Lhx3W227ter/W227ter pituitaries. Scale bars = 200 
μm. C. Real-time quantitative PCR analyses show that the Pomc transcript is slightly 
decreased in the Lhx3W227ter/W227ter mutant mice (KI/KI) at 12 weeks of age, although this 
decrease is not significant.  
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Figure 3.8. Altered gene expression of transcription factors involved in pituitary 
development. A-B. Examination of transcript levels of Lhx3a&b via real-time qPCR 
revealed a significant decrease in both Lhx3+/W227ter heterozygote (+/KI) and 
Lhx3W227ter/W227ter homozygote (KI/KI) mice at both 6 weeks (A) and 12 weeks of age (B). 
C. Pit-1 transcript was found to be decreased in the knock-in mice at 12 weeks of age. D. 
Transcript levels of Pitx1 were increased in Lhx3W227ter/W227ter mutant mice in comparison 
to wild-type controls (+/+). E.  Lhx4 transcript levels were not significantly different in 
the Lhx3W227ter/W227ter knock-in mice compared to wild-type controls.  Asterisks (*) 
indicate significance when compared to wild type controls with p<0.05. 
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CHAPTER FOUR 
 
DISCUSSION AND CONCLUSIONS 
 
 
 
We have made a new dwarf mouse model that models the human disease caused 
by the W224ter mutation within the LHX3 gene. As for the Lhx3 knockout mice that die 
within 24 hours of birth (Sheng, Zhadanov et al. 1996), the Lhx3W227ter/W227ter knock-in 
mice survive and are represented in the expected numbers in the offspring from 
heterozygous crosses. Mice heterozygous for the Lhx3W227ter mutation appear to be 
phenotypically normal in comparison to wild-type animals, in accordance with 
observations of patient and animals with only one functioning Lhx3 allele (Sheng, 
Zhadanov et al. 1996; Pfaeffle, Savage et al. 2007; Savage, Hunter et al. 2007). However, 
the homozygous knock-in mice have reduced levels of GH, TSH, IGF-1, T4, LH, FSH, 
and PRL, which manifests phenotypically in the mice with dwarfism, reduced fertility in 
the male knock-in mice, and infertility in the female knock-in mice. The truncated LHX3 
protein resulting from the Lhx3W227ter mutation appears to have similar actions in both 
mice and humans as the hormone deficiencies and phenotype of the Lhx3W227ter/W227ter 
knock-in mice mimics that of the human patients (Pfaeffle, Savage et al. 2007; Savage, 
Hunter et al. 2007). In addition to the expected deficiencies in hormones in the knock-in 
mice, IHC staining in pituitaries of Lhx3W227ter/W227ter mice indicated that ACTH-positive 
cells were reduced in the knock-in mice at both P1 and at 12 weeks of age. Pomc 
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transcript levels were also decreased at 12 weeks of age in the knock-in mice. While 
ACTH deficiency is not associated with this particular mutation in the human patients, 
other mutations within the LHX3 gene have been linked with ACTH deficiency and the 
population of corticotropes that is found in the Lhx3-/- mice is diminished (Sheng, 
Zhadanov et al. 1996; Colvin, Mullen et al. 2009). More experiments are necessary to 
determine if the reduction in the ACTH-producing cells within the pituitaries of the 
Lhx3W227ter/W227ter knock-in mice results in lower serum ACTH levels and potentially 
reduced serum corticosterone levels.   
The growth insufficiency seen in the Lhx3W227ter/W227ter knock-in mice is likely due 
to the deficiencies in GH, IGF-1, TSH, and T4 as all of these proteins appeared to be 
significantly reduced in the knock-in mice when compared to wild-type controls. 
However, real-time qPCR analyses revealed an increase in Tshb transcript levels at both 6 
weeks and 12 weeks of age. This is presumably due to a feedback mechanism where the 
low circulating T3 and T4 hormone levels are feeding back to the pituitary in an attempt to 
increase pituitary output of TSH as has been shown by Shupnik et al. (1985). However, 
IHC staining demonstrated a decrease in thyrotrope cell numbers within the anterior 
pituitaries of the knock-in mice at both P1 and 12 weeks of age, and real-time qPCR 
revealed a decrease in transcript levels of the alpha subunit (Gsu) of TSH at both 6 
weeks and 12 weeks of age. Overall, something is impairing the ability of the pituitary to 
release appropriate levels of TSH, whether it is the paucity of thyrotrope cells or the 
potential rate-limiting decrease in the production of GSU, although this would be a 
different mechanism to the model mentioned by Shupnik et al. (1985) in which it is the 
beta subunit of TSH that is considered the rate-limiting step in the production of TSH 
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hormone. This fits with known roles of LHX3 in both cell proliferation (Sheng, 
Moriyama et al. 1997; Raetzman, Ward et al. 2002; Ellsworth, Butts et al. 2008) and gene 
activation of both GSU and TSHβ (Bach, Rhodes et al. 1995; Sloop, Meier et al. 1999).  
The growth insufficiency of the Lhx3W227ter/W227ter knock-in mice, while significant 
when compared to wild-type animals, does not appear to be as severe as the growth 
insufficiency seen in other dwarf mouse models. At 8 weeks of age, the Lhx3W227ter/W227ter 
knock-in mice appear to be approximately twice the size of Snell dwarf mice (Pit-1dw), 
the Ames dwarf mice (Prop1df), the Prop1 knockout mice, and the Jackson dwarf mice 
(Pit-1dw-J) (Eicher and Beamer 1980; Li, Crenshaw et al. 1990; Gage, Lossie et al. 1995; 
Gage, Roller et al. 1996; Nasonkin, Ward et al. 2004). This could be due to varying 
hormone levels across the different dwarf mouse models. The pituitary hypoplasia and 
hormone deficiency in the Lhx3W227ter/W227ter knock-in mice does not appear to be as 
severe as that seen in the aforementioned dwarf mouse models (Eicher and Beamer 1980; 
Li, Crenshaw et al. 1990; Gage, Lossie et al. 1995; Gage, Roller et al. 1996; Nasonkin, 
Ward et al. 2004). This indicates that the truncated LHX3W227ter protein retains some 
residual function in vivo, which is supported by several in vitro assays demonstrating 
some function of this truncated protein (Savage, Hunter et al. 2007). The hypocellularity 
of the pituitaries of the Lhx3W227ter/W227ter knock-in mice needs to be investigated further 
and more experiments need to be done to determine if the hypocellularity is due to an 
increase in apoptosis or a decrease in proliferation during pituitary development.     
The Lhx3W227ter/W227ter knock-in mice also have compromised fertility. The male 
knock-in mice have reduced fertility while the female knock-in mice are completely 
infertile. IHC indicates reduced levels of LH- and FSH-producing cells in the 
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Lhx3W227ter/W227ter mice at 12 weeks of age, but real-time qPCR analyses showed an 
increase in Lhb and Fshb transcript at this time point. As for TSH, this is presumably due 
to a feedback mechanism where the low circulating sex steroid hormone levels are 
feeding back to the pituitary in an attempt to increase pituitary output of LH and FSH. 
However, IHC staining demonstrated a decrease in gonadotrope cells within the anterior 
pituitaries of the knock-in mice at both P1 and 12 weeks of age, and real-time qPCR 
revealed a decrease in transcript levels of the alpha subunit (Gsu = Cga) of both of LH 
and FSH hormones at both 6 weeks and 12 weeks of age. Again, it is not clear whether it 
is the decrease in gonadotrope cells within the anterior pituitaries or the potential rate-
limiting decrease in the production of GSU that is causing the presumed decreased 
pituitary output of LH and FSH in the Lhx3W227ter/W227ter knock-in mice. However, while 
IHC indicates LH and FSH are reduced in the knock-in mice, histological evidence 
suggests these hormones are not completely absent. The male knock-in mice have 
seminal vesicles that are proportionally smaller and weigh significantly less than their 
wild-type counterparts at 6 weeks of age. At the same time point, histological 
examination of the seminal vesicles and prostate glands of male mutant mice show a 
decrease in secretous material and the testes show no evidence of spermatogenesis. These 
data indicate a delay in puberty and testosterone production in the male Lhx3W227ter/W227ter 
knock-in mice presumably due to LH deficiency as observed in LH-/- mice (Kumar, 
Wang et al. 1997; Ma, Dong et al. 2004). The size of the seminal vesicles of the knock-in 
male mice at 12 weeks is still smaller than those of their wild-type counterparts, 
indicating lower testosterone levels. At 6 weeks of age, the sizes of the testes and prostate 
glands of the male knock-in mice are consistently smaller compared to those of the wild-
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type controls presumably due to decreases in LH and FSH as male mice with a complete 
knockout of either LH or FSH also have smaller testes and prostate glands (Kumar, 
Wang et al. 1997; Ma, Dong et al. 2004). However, although puberty appears to be 
delayed in the male knock-in mice, they are eventually able to reproduce, albeit at a 
reduced rate compared to heterozygote controls. This pubertal delay is presumably due to 
the decrease in LH hormone levels which then leads to reduced testosterone levels. While 
LH appears to be reduced, it is not completely absent in the male Lhx3W227ter/W227ter 
knock-in mice as indicated by their reduced fertility; by contrast, LH-null male mice are 
sterile (Ma, Dong et al. 2004). This suggests that enough LH is present for the male 
Lhx3W227ter/W227ter knock-in mice to eventually become fertile. Although PRL becomes 
almost completely absent in the Lhx3W227ter/W227ter knock-in mice, the lack of PRL does 
not appear to be the cause of reduced fertility in the male knock-in mice because PRL 
knockouts are fully fertile and able to reproduce at the same rate as wild-type controls 
(Horseman, Zhao et al. 1997). More experiments are necessary to further investigate the 
cause of the reduced fertility of the male Lhx3W227ter/W227ter knock-in mice. These might 
include measuring serum LH levels, and measuring serum and testicular testosterone 
levels at various timepoints with the male Lhx3W227ter/W227ter knock-in mice in an attempt 
to determine the point in time at which these hormone levels reach the necessary 
threshold for reproduction to occur.  
In contrast to the male Lhx3W227ter/W227ter knock-in mice having only reduced 
fertility, the female knock-in mice are infertile. As mentioned previously, the 
Lhx3W227ter/W227ter mice have reduced levels of LH- and FSH-producing cells, however, 
histological analyses indicate there are enough circulating gonadotropins for normally-
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functioning ovaries in the female Lhx3W227ter/W227ter knock-in mice whereas the ovaries of 
both the LH knockout mice and the FSH knockout mice have abnormal 
folliculogenesis and an absence of corpora lutea indicating no ovulation is taking place 
(Kumar, Wang et al. 1997; Ma, Dong et al. 2004). PRL levels are strikingly low in the 
Lhx3W227ter/W227ter knock-in mice. Within the ovary, PRL is required for the proper 
maintenance of the corpus luteum. The PRL knockout mice appear to ovulate normally, 
as do the female Lhx3W227ter/W227ter knock-in mice. However, PRL knockout female mice 
are also infertile (Horseman, Zhao et al. 1997). One of the important roles of PRL in 
reproduction is that it stimulates the production of progesterone by the corpus luteum 
within the ovaries, which is then responsible for implantation of embryos, maintenance of 
pregnancy, and the inhibition of ovulation (Bole-Feysot, Goffin et al. 1998). We believe 
the infertility of the female Lhx3W227ter/W227ter mice is due to the PRL deficiency seen in 
these mice. If the pituitary glands of the female Lhx3W227ter/W227ter knock-in mice are not 
producing adequate amounts of PRL, then the corpus luteum is probably not receiving 
enough PRL support and the appropriate signals for implantation that are dependent on 
progesterone and estrogen signaling cannot occur (Ormandy, Camus et al. 1997). More 
experiments need to be done with the female knock-in mice to verify that implantation is 
impaired, for example, implanting wild-type embryos into the uteri of female 
Lhx3W227ter/W227ter knock-in mice to determine if implantation can occur. If possible, 
embryos flushed from the oviducts of female Lhx3W227ter/W227ter knock-in mice should also 
be implanted into the uteri of wild-type female mice to determine that the infertility of the 
female Lhx3W227ter/W227ter knock-in mice is due to an implantation problem versus a 
problem with the eggs being viable. Serum progesterone and estrogen levels should also 
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be measured in the mice to verify a disruption in hormone signaling. It would be 
interesting to attempt to rescue this reproductive phenotype seen in the female 
Lhx3W227ter/W227ter knock-in mice with exogenous PRL hormone treatments.    
Histological examination of the uteri of female Lhx3W227ter/W227ter mice suggests 
that estrous is impaired in these animals. The uterine wall of 6 week old wild-type mice 
displayed varying thicknesses and levels of keratinization representing the various stages 
of estrous; however, the uterine wall of knock-in mice displayed only one kind of 
phenotype: a thin uterine wall with no keratinization suggestive of an immature uterus. 
The uteri of female knock-in mice were proportionally smaller and weighed significantly 
less than those of wild-type female mice at 6 weeks of age, and overall appeared thinner 
compared to uteri of wild-type female mice. However, the reduced size of the uteri of 
Lhx3W227ter/W227ter mice does not appear to be as drastic as the uteri of LH- and FSH- 
knockout mice (Kumar, Wang et al. 1997; Ma, Dong et al. 2004). It is not obvious why 
the estrous cycles of the knock-in mice are impaired as there appears to be enough LH 
and FSH present for normally functioning ovaries. It is possible that there is a threshold 
amount of LH and FSH required for appropriate estrous cycling; however, PRL knockout 
mice and PRLR knockout mice with normal LH and FSH levels also have aberrant 
estrous cycles (Horseman, Zhao et al. 1997; Ormandy, Camus et al. 1997). Typically, 
after a vaginal plug is observed, the female mice will go into a pseudopregnant state and 
refrain from mating for about 12 days. However, in both the PRL-/- and PRLR-/- female 
mice, a pseudopregnant state was never observed after vaginal plugs were noted as the 
animals mated again 3-4 days later. This indicates PRL may have a role for the 
establishment and maintenance of pseudopregnancy (Gunnet and Freeman 1983; 
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Horseman, Zhao et al. 1997; Ormandy, Camus et al. 1997). Additional experiments are 
needed to determine how often the female knock-in mice go into estrous using vaginal 
smear cytology and how frequently they mate. Serum LH and FSH levels should also be 
measured.   
Several genes within the transcription factor cascade essential for proper anterior 
pituitary development were examined in the mice at 12 weeks of age via real-time qPCR, 
and aberrant expression of every gene examined was noted in the Lhx3W227ter/W227ter mice. 
A decrease in the Lhx3a and Lhx3b transcripts was noted in both heterozygous and 
knock-in mice, with the decrease in the knock-in mice significantly different from wild-
type controls. It appears as though the Lhx3 transcript containing the introduced point 
mutation may be subjected to some nonsense-mediated decay and/or instability, although 
more experiments need to be done to confirm this. Also, assuming the reduction in 
Lhx3W227ter transcript levels results in reduced LHX3W227ter protein levels, the 
overall reduction in LHX3W227ter protein levels or the effect of the mutation itself could 
be affecting the ability of the LHX3 protein to autoregulate its own transcription. 
Although it is not known if LHX3 is capable of regulating transcription of its own gene, 
other transcription factors are known to do this, for example, the PIT-1 transcription 
factor is capable of activating transcription of its own gene (Rhodes, Krones et al. 1996). 
However, enough truncated protein must be produced for the Lhx3W227ter/W227ter mice to be 
viable as mice homozygous for a null Lhx3 allele die within 24 hours of birth (Sheng, 
Zhadanov et al. 1996). The truncated LHX3W227ter protein does not appear to be 
exerting any dominant negative effects as Lhx3+/W227ter heterozygous mice appear to be 
unaffected. Lhx4 transcript levels were also examined in the Lhx3W227ter/W227ter mice to test 
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the hypothesis that LHX4 expression levels may be increased in an effort to compensate 
for any loss of LHX3 expression and/or function in the knock-in mice. However, no 
significant difference in Lhx4 transcript levels was noted in the Lhx3W227ter/W227ter mice. 
The PIT-1 transcription factor acts downstream of LHX3 within the transcription factor 
cascade involved in anterior pituitary development (Colvin, Mullen et al. 2009). It has 
been shown to be essential for the proper development of the thyrotrope cells, 
somatotrope cells, and lactotrope cells within the anterior pituitary (Li, Crenshaw et al. 
1990; Dasen, O'Connell et al. 1999; Scully and Rosenfeld 2002). Pit-1 transcript levels 
were found to be significantly reduced in the Lhx3W227ter/W227ter mice in comparison to 
wild-type controls. As LHX3 has been shown to be able to bind and activate transcription 
from the Pit-1 promoter (Bach, Rhodes et al. 1995), this reduction in Pit-1 transcript seen 
in the knock-in mice could be due to the reduction in overall production of LHX3 protein 
in the knock-in mice or due to the fact that there are less cells of the Pit-1 lineage in the 
knock-in mouse pituitaries. Another possibility is that the truncated LHX3 protein itself 
has a reduced ability to bind and activate the Pit-1 promoter in the knock-in mice, as 
some in vitro work suggests this truncated protein may not retain full function (Bach, 
Rhodes et al. 1995; Pfaeffle, Savage et al. 2007; Savage, Hunter et al. 2007). PITX1 is a 
transcription factor thought to act upstream of LHX3 within the cascade of genes 
involved in pituitary development. Pitx1 transcript levels were significantly increased in 
Lhx3W227ter/W227ter mice compared to wild-type controls. Several possible scenarios may 
explain this increase in Pitx1 transcript. As mentioned previously, PITX1 has been shown 
to have a role in the activation of several genes involved in pituitary development and/or 
function. It has a role in the activation of the POMC gene, and it is able to bind and 
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activate transcription of PRL, LH, FSH, TSH, GnRHR, and GH (Lamonerie, 
Tremblay et al. 1996; Szeto, Ryan et al. 1996; Lanctot, Lamolet et al. 1997; Tremblay, 
Lanctot et al. 1998; Lanctot, Moreau et al. 1999; Jeong, Chin et al. 2004). PITX1 has also 
been shown to have a role in the proper expression of LHX3 and GSU (Tremblay, 
Lanctot et al. 1998; Charles, Suh et al. 2005). All of the pituitary targets of PITX1 have 
altered expression in the Lhx3W227ter/W227ter mice, with most of them being decreased (Lhb, 
Fshb, and Tshb transcript levels being exceptions). Perhaps Pitx1 transcript levels are 
increased in Lhx3W227ter/W227ter mice in an effort to increase production of its pituitary 
target genes, for example, the increases seen in Lhb, Fshb, and Tshb transcript levels. 
However, the mechanism causing this increase in Pitx1 transcript is not known.  
No nervous system defects have been found in the Lhx3W227ter/W227ter mice. While 
the LHX3W224ter mutation does not cause a nervous system phenotype in the human 
patients, other mutations within the human LHX3 gene are associated with a rigid cervical 
spine resulting in limited head rotation of the patients. The nervous system phenotype 
seen in human patients with LHX3 mutations is presumably due to the role of LHX3 
within the developing nervous system. Previous work indicates that the LIM domains and 
homeodomain of LHX3 are required for the formation of a multiprotein complex 
necessary for spinal cord motor neuron development, and in animals lacking both LHX3 
and LHX4, V2 interneurons and ventral motor neurons do not develop properly (Sharma, 
Sheng et al. 1998; Thor, Andersson et al. 1999; Thaler, Lee et al. 2002). Since the 
Lhx3W227ter/W227ter mice supposedly have normal expression of LHX4, perhaps the lack of 
nervous system phenotype in the knock-in mice is due to compensation of LHX4 within 
the V2 interneuron and ventral motor neuron cells of the developing spinal cord. It would 
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be beneficial to examine the expression of the LHX4 transcription factor within the 
nervous system of the Lhx3W227ter/W227ter mice to first determine if its expression pattern is 
normal compared to wild type controls. Second, in order to determine more accurately 
whether the mutant LHX3W227ter protein is capable of functioning in the developing 
nervous system on its own without compensation by LHX4, the Lhx3W227ter/W227ter mice 
should be crossed with Lhx4+/- heterozygous animals and progeny should be bred to 
produce Lhx3W227ter/W227ter/Lhx4-/- mice. Analyses of the nervous systems of these animals 
should give further insight as to whether the LHX3W227ter protein is able to retain 
function within the developing nervous system. Another problem with analyzing the 
nervous system in the Lhx3W227ter/W227ter mice is that it is not certain how this rigid 
cervical spine resulting in limited head rotation seen in the human patients would present 
itself phenotypically within mice. One way to examine this would be to generate mice 
containing a knock-in mutation of the LHX3A210V mutation that is known to cause this 
neck phenotype seen in the human patients. However, as these mice would presumably 
have normal LHX4 in the nervous system, the nervous system phenotype may not present 
itself phenotypically until the animals were bred to obtain an Lhx3A210V/A210V/Lhx4-/- 
genotype. If it were possible to generate mice with similar nervous system defects as 
those seen in the human patients, it would prove difficult to examine the extent of the 
phenotype. One benefit to investigating the molecular effects these mutations exert within 
mice is that the cell populations within the developing spinal cord can be examined using 
IHC at various time points. However, there are presumed limitations when it comes to 
measuring the level of neck rigidity and impaired head rotation in mice versus humans. 
Human patients are asked to sit in a chair and look at various points within the room. This 
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kind of task cannot be performed as easily with mice. However, some attempt must be 
made to measure various behavioral tasks to determine whether this limited head rotation 
seen in the human patients can also be seen in the mice. For example, are the mutant 
knock-in animals able to reach around and groom themselves properly, do they exhibit 
normal cage behavior (can they rear up to reach food and/or water), would they respond 
differently than their wild type counterparts during a startle response task. Further 
exmaination into the nervous system of the Lhx3W227ter/W227ter mice is warranted.  
Given the limited examination into the nervous systems of the Lhx3W227ter/W227ter 
mice, again, no nervous system defects have been observed in these mice to date. Work 
done by other groups indicates that the LIM domains and homeodomain of LHX3 are 
required for the formation of a multiprotein complex necessary for spinal cord motor 
neuron development (Sharma, Sheng et al. 1998; Thor, Andersson et al. 1999; Thaler, 
Lee et al. 2002). And although the carboxyl terminus of LHX3 contains the major trans-
activation domain of the protein that could allow regulation of LHX3 function and 
location through signaling pathways, the LIM domains also appear to contain some 
activation function that may serve a role in the nervous system (Parker, Sandoval et al. 
2000; Sloop, Showalter et al. 2000; Parker, West et al. 2005). The fact that the mice 
survive into adulthood indicates that the truncated LHX3 protein is not only being made, 
but that it is retaining enough function to produce viable mice. Mice without any 
functional LHX3 protein are stillborn or die within 24 hours after birth, and Lhx3Cre/Cre 
mice with reduced Lhx3 mRNA and protein levels recapitulate the phenotype seen in 
Lhx3 knockout mice in that they do not survive within 24 hours of birth and display 
similar pituitary problems (Sheng, Zhadanov et al. 1996; Zhao, Morales et al. 2006). This 
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indicates that there may be some threshold level of LHX3 necessary for survival that the 
Lhx3W227ter/W227ter mice are attaining whereas the Lhx3Cre/Cre mice fall below this threshold 
level. While the Lhx3-/- mice and the Lhx3Cre/Cre mice do not express any or enough LHX3 
to survive, the ex act cause of death in the Lhx3Cre/Cre and the Lhx3-/- mice has not been 
determined. It has been speculated that these animals die from impaired brain stem 
function due to a lack of LHX3 expression in precursor cells of the Raphe nuclei and 
reticular formation (Zhadanov, Bertuzzi et al. 1995; Sheng, Zhadanov et al. 1996). 
Although the exact role of LHX3 in the developing brain stem has yet to be determined, 
this emphasizes the importance of LHX3 expression in the developing nervous system. 
Previous data has demonstrated that the LIM domains and the homeodomain of LHX3 
are vital for protein-protein interaction in the LIM code that specifies V2 interneurons 
from motor neurons in the developing spinal cord (Sharma, Sheng et al. 1998; Thaler, 
Lee et al. 2002), and data from our laboratory indicates that the LHX3W224Ter protein is 
able to act in synergy with its partner proteins to activate transcription from the Hb9 
motor neuron enhancer (Savage, Hunter et al. 2007). IHC staining with both motor 
neuron (Hb9) and V2 interneuron markers (CHX10) in the developing spinal cords of 
Lhx3W227ter/W227ter knock-in mice revealed no abnormalities (data not shown). While an 
attempt was made to detect the LHX3W227ter mutant protein within the pituitaries and 
nervous systems of the knock-in animals, most antibodies made for the LHX3 protein are 
polyclonal for the carboxyl terminus of the protein. Since the LHX3W227ter mutant 
protein does not retain the carboxyl terminus, these antibodies could not be used for 
detection. One antibody that was said to react with the amino terminus of the LHX3 
protein did not give reliable staining results; however, if a good antibody for the amino-
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terminus of LHX3 were available, or if the mice had been made with a Myc or HA tag 
attached to Lhx3, it would be beneficial to use chromatin immunoprecipitation (ChIP) 
assays to determine if the LHX3W227ter protein is able to bind to its pituitary targets 
with the same efficiency as its nervous system targets. Even without a method for 
detection of the LHX3W227ter protein, ChIP assays could be used to determine whether 
target genes of LHX3 were in a transcriptionally active state using an acetylated histone 
H3 antibody, and whether more target genes of LHX3 in the nervous system would be 
active versus those in the pituitary gland. However, the lack of a nervous system 
phenotype in the Lhx3W227ter/W227ter knock-in mice support the hypothesis that the LIM 
domains and the homeodomain of LHX3 are all that are required for it to function 
properly during nervous system development. However, the carboxyl terminus of LHX3 
is necessary for the proper development of the anterior pituitary as the hormone 
deficiencies seen in both the human patients and the knock-in mice suggests. 
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